"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","characteristics_ch1.5","characteristics_ch1.6","characteristics_ch1.7","characteristics_ch1.8","characteristics_ch1.9","characteristics_ch1.10","characteristics_ch1.11","characteristics_ch1.12","characteristics_ch1.13","characteristics_ch1.14","characteristics_ch1.15","treatment_protocol_ch1","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","data_processing","platform_id","contact_name","contact_email","contact_laboratory","contact_department","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","age:ch1","cancer recurrance after surgery:ch1","death due to tumor:ch1","depth of invasion after rct:ch1","depth of invasion before rct:ch1","disease free time (month):ch1","gender:ch1","kras mutation:ch1","lymph node metastasis after rct:ch1","lymph node metastasis before rct:ch1","metastasis after rct:ch1","metastasis before rct:ch1","patient:ch1","preoperative radiochemotherapy (rct):ch1","survival time (month):ch1","tissue:ch1"
"GSM2325238","Patient 1 tumor sample","GSM2325238","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 1","age: 55.6","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -4.08","death due to tumor: 0","survival time (month): 41.92","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325238/suppl/GSM2325238_US22502691_252665211104_S01_GE1_107_Sep09_1_1.txt.gz","34127","55.6","1","0","3","3","-4.08","F","WT","1","1","1","1","Tum Patient 1","5-FU + Oxaliplatin + RT","41.92","rectal tumor"
"GSM2325239","Patient 2 tumor sample","GSM2325239","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 2","age: 65.6","gender: M","tissue: rectal tumor","kras mutation: I21L","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 40.27","death due to tumor: 0","survival time (month): 40.27","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325239/suppl/GSM2325239_US22502691_252665211182_S01_GE1_107_Sep09_1_1.txt.gz","34127","65.6","0","0","0","3","40.27","M","I21L","0","1","0","0","Tum Patient 2","5-FU + RT","40.27","rectal tumor"
"GSM2325240","Patient 3 tumor sample","GSM2325240","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 3","age: 62.7","gender: M","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 29.62","death due to tumor: 0","survival time (month): 29.62","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325240/suppl/GSM2325240_US22502691_252665211184_S01_GE1_107_Sep09_1_3.txt.gz","34127","62.7","0","0","0","3","29.62","M","G12D","0","0","0","0","Tum Patient 3","5-FU + RT","29.62","rectal tumor"
"GSM2325241","Patient 4 tumor sample","GSM2325241","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 4","age: 61.8","gender: M","tissue: rectal tumor","kras mutation: G12A","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 32.65","death due to tumor: 0","survival time (month): 32.65","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325241/suppl/GSM2325241_US22502691_252665211155_S01_GE1_107_Sep09_1_3.txt.gz","34127","61.8","0","0","0","3","32.65","M","G12A","0","1","0","0","Tum Patient 4","5-FU + Oxaliplatin + RT","32.65","rectal tumor"
"GSM2325242","Patient 5 tumor sample","GSM2325242","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 5","age: 52.1","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 31.59","death due to tumor: 0","survival time (month): 31.59","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325242/suppl/GSM2325242_US22502691_252665211157_S01_GE1_107_Sep09_1_1.txt.gz","34127","52.1","0","0","0","3","31.59","F","WT","0","1","0","0","Tum Patient 5","5-FU + RT","31.59","rectal tumor"
"GSM2325243","Patient 6 tumor sample","GSM2325243","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 6","age: 59.1","gender: M","tissue: rectal tumor","kras mutation: G12C","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 34.52","death due to tumor: 0","survival time (month): 34.52","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325243/suppl/GSM2325243_US22502691_252665211176_S01_GE1_107_Sep09_1_1.txt.gz","34127","59.1","0","0","2","3","34.52","M","G12C","0","0","0","0","Tum Patient 6","5-FU + Oxaliplatin + RT","34.52","rectal tumor"
"GSM2325244","Patient 7 tumor sample","GSM2325244","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 7","age: 70.7","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 32.68","death due to tumor: 0","survival time (month): 32.68","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325244/suppl/GSM2325244_US22502691_252665211159_S01_GE1_107_Sep09_1_1.txt.gz","34127","70.7","0","0","0","3","32.68","M","WT","0","0","0","0","Tum Patient 7","5-FU + RT","32.68","rectal tumor"
"GSM2325245","Patient 8 tumor sample","GSM2325245","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 8","age: 60.7","gender: M","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 30.31","death due to tumor: 0","survival time (month): 30.31","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325245/suppl/GSM2325245_US22502691_252665211203_S01_GE1_107_Sep09_1_3.txt.gz","34127","60.7","0","0","2","3","30.31","M","G12D","0","1","0","0","Tum Patient 8","5-FU + RT","30.31","rectal tumor"
"GSM2325246","Patient 9 tumor sample","GSM2325246","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 9","age: 55","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 28.08","death due to tumor: 0","survival time (month): 28.08","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325246/suppl/GSM2325246_US22502691_252665211065_S01_GE1_107_Sep09_1_3.txt.gz","34127","55","0","0","2","3","28.08","M","WT","0","0","0","0","Tum Patient 9","5-FU + Oxaliplatin + RT","28.08","rectal tumor"
"GSM2325247","Patient 10 tumor sample","GSM2325247","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 10","age: 53.1","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 27.55","death due to tumor: 0","survival time (month): 27.55","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325247/suppl/GSM2325247_US22502691_252665211069_S01_GE1_107_Sep09_1_1.txt.gz","34127","53.1","0","0","3","3","27.55","M","WT","1","1","0","0","Tum Patient 10","5-FU + RT","27.55","rectal tumor"
"GSM2325248","Patient 11 tumor sample","GSM2325248","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 11","age: NA","gender: M","tissue: rectal tumor","kras mutation: A146T","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: NA","lymph node metastasis after rct: NA","metastasis after rct: NA","cancer recurrance after surgery: 0","disease free time (month): NA","death due to tumor: 0","survival time (month): NA","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325248/suppl/GSM2325248_US22502691_252665211219_S01_GE1_107_Sep09_1_3.txt.gz","34127","NA","0","0","NA","3","NA","M","A146T","NA","0","NA","0","Tum Patient 11","5-FU + Oxaliplatin + RT","NA","rectal tumor"
"GSM2325249","Patient 12 tumor sample","GSM2325249","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 12","age: 58.6","gender: M","tissue: rectal tumor","kras mutation: G12C","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 14.93","death due to tumor: 0","survival time (month): 14.93","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325249/suppl/GSM2325249_US22502691_252665211214_S01_GE1_107_Sep09_1_3.txt.gz","34127","58.6","0","0","2","3","14.93","M","G12C","1","0","0","0","Tum Patient 12","5-FU + RT","14.93","rectal tumor"
"GSM2325250","Patient 13 tumor sample","GSM2325250","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 13","age: 68.5","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 23.38","death due to tumor: 0","survival time (month): 23.38","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325250/suppl/GSM2325250_US22502691_252665211189_S01_GE1_107_Sep09_1_3.txt.gz","34127","68.5","0","0","0","3","23.38","M","WT","0","1","0","0","Tum Patient 13","5-FU + RT","23.38","rectal tumor"
"GSM2325251","Patient 14 tumor sample","GSM2325251","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 14","age: 58.8","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 2","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 6.71","death due to tumor: 0","survival time (month): 25.81","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325251/suppl/GSM2325251_US22502691_252665211086_S01_GE1_107_Sep09_1_1.txt.gz","34127","58.8","1","0","3","2","6.71","M","WT","1","1","1","1","Tum Patient 14","5-FU + Oxaliplatin + RT","25.81","rectal tumor"
"GSM2325252","Patient 15 tumor sample","GSM2325252","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 15","age: 70.1","gender: M","tissue: rectal tumor","kras mutation: G12S","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: NA","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 13.02","death due to tumor: 0","survival time (month): 13.02","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325252/suppl/GSM2325252_US22502691_252665211088_S01_GE1_107_Sep09_1_1.txt.gz","34127","70.1","0","0","2","NA","13.02","M","G12S","1","1","0","0","Tum Patient 15","5-FU + Oxaliplatin + RT","13.02","rectal tumor"
"GSM2325253","Patient 16 tumor sample","GSM2325253","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 16","age: 77.6","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: NA","metastasis before rct: NA","depth of invasion after rct: 4","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 34.72","death due to tumor: 0","survival time (month): 34.72","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325253/suppl/GSM2325253_US22502691_252665211183_S01_GE1_107_Sep09_1_1.txt.gz","34127","77.6","0","0","4","3","34.72","F","G12D","0","NA","0","NA","Tum Patient 16","5-FU + RT","34.72","rectal tumor"
"GSM2325254","Patient 17 tumor sample","GSM2325254","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 17","age: 68.5","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: NA","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -2.63","death due to tumor: 0","survival time (month): 18.28","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325254/suppl/GSM2325254_US22502691_252665211213_S01_GE1_107_Sep09_1_3.txt.gz","34127","68.5","1","0","3","3","-2.63","F","WT","2","NA","1","1","Tum Patient 17","5-FU + RT","18.28","rectal tumor"
"GSM2325255","Patient 18 tumor sample","GSM2325255","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 18","age: 75.2","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: NA","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -3.32","death due to tumor: 1","survival time (month): 10.26","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325255/suppl/GSM2325255_US22502691_252665211213_S01_GE1_107_Sep09_1_1.txt.gz","34127","75.2","1","1","3","3","-3.32","M","WT","2","NA","1","1","Tum Patient 18","5-FU + RT","10.26","rectal tumor"
"GSM2325256","Patient 19 tumor sample","GSM2325256","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 19","age: 76.3","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: NA","metastasis before rct: NA","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 10.62","death due to tumor: 0","survival time (month): 10.62","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325256/suppl/GSM2325256_US22502691_252665211205_S01_GE1_107_Sep09_1_1.txt.gz","34127","76.3","0","0","3","3","10.62","M","WT","0","NA","0","NA","Tum Patient 19","5-FU + RT","10.62","rectal tumor"
"GSM2325257","Patient 20 tumor sample","GSM2325257","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 20","age: 38.2","gender: M","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 8.25","death due to tumor: 0","survival time (month): 8.25","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325257/suppl/GSM2325257_US22502691_252665211098_S01_GE1_107_Sep09_1_1.txt.gz","34127","38.2","0","0","2","3","8.25","M","G13D","0","1","0","0","Tum Patient 20","5-FU + RT","8.25","rectal tumor"
"GSM2325258","Patient 21 tumor sample","GSM2325258","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 21","age: 61.1","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -0.62","death due to tumor: 1","survival time (month): 5.75","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325258/suppl/GSM2325258_US22502691_252665211099_S01_GE1_107_Sep09_1_1.txt.gz","34127","61.1","1","1","3","3","-0.62","F","WT","2","0","1","1","Tum Patient 21","5-FU + RT","5.75","rectal tumor"
"GSM2325259","Patient 22 tumor sample","GSM2325259","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 22","age: 69.4","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 23.28","death due to tumor: 0","survival time (month): 23.28","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325259/suppl/GSM2325259_US22502691_252665211171_S01_GE1_107_Sep09_1_3.txt.gz","34127","69.4","0","0","3","3","23.28","M","WT","0","0","0","0","Tum Patient 22","5-FU + Oxaliplatin + RT","23.28","rectal tumor"
"GSM2325260","Patient 23 tumor sample","GSM2325260","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 23","age: 54.2","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 23.8","death due to tumor: 0","survival time (month): 23.8","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325260/suppl/GSM2325260_US22502691_252665211171_S01_GE1_107_Sep09_1_1.txt.gz","34127","54.2","0","0","2","3","23.8","M","WT","0","0","0","0","Tum Patient 23","5-FU + RT","23.8","rectal tumor"
"GSM2325261","Patient 24 tumor sample","GSM2325261","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 24","age: 57.4","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 7.33","death due to tumor: 0","survival time (month): 7.33","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325261/suppl/GSM2325261_US22502691_252665211161_S01_GE1_107_Sep09_1_1.txt.gz","34127","57.4","0","0","1","3","7.33","F","WT","0","0","0","0","Tum Patient 24","5-FU + Oxaliplatin + RT","7.33","rectal tumor"
"GSM2325262","Patient 25 tumor sample","GSM2325262","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 25","age: 61.3","gender: M","tissue: rectal tumor","kras mutation: Q61P","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 15.25","death due to tumor: 0","survival time (month): 24.1","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325262/suppl/GSM2325262_US22502691_252665211204_S01_GE1_107_Sep09_1_1.txt.gz","34127","61.3","1","0","3","3","15.25","M","Q61P","0","1","0","0","Tum Patient 25","5-FU + RT","24.1","rectal tumor"
"GSM2325263","Patient 26 tumor sample","GSM2325263","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 26","age: 47","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 22.55","death due to tumor: 0","survival time (month): 22.55","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325263/suppl/GSM2325263_US22502691_252665211066_S01_GE1_107_Sep09_1_1.txt.gz","34127","47","0","0","3","3","22.55","M","WT","0","1","0","0","Tum Patient 26","5-FU + Oxaliplatin + RT","22.55","rectal tumor"
"GSM2325264","Patient 27 tumor sample","GSM2325264","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 27","age: 62.7","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 22.22","death due to tumor: 0","survival time (month): 22.22","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325264/suppl/GSM2325264_US22502691_252665211208_S01_GE1_107_Sep09_1_3.txt.gz","34127","62.7","0","0","0","3","22.22","M","WT","0","0","0","0","Tum Patient 27","5-FU + RT","22.22","rectal tumor"
"GSM2325265","Patient 28 tumor sample","GSM2325265","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 28","age: 51.3","gender: M","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 17.98","death due to tumor: 0","survival time (month): 17.98","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325265/suppl/GSM2325265_US22502691_252665211222_S01_GE1_107_Sep09_1_3.txt.gz","34127","51.3","0","0","0","3","17.98","M","G13D","0","1","0","0","Tum Patient 28","5-FU + RT","17.98","rectal tumor"
"GSM2325266","Patient 29 tumor sample","GSM2325266","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 29","age: 73.3","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 1","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 0","death due to tumor: 0","survival time (month): 6.25","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325266/suppl/GSM2325266_US22502691_252665211207_S01_GE1_107_Sep09_1_1.txt.gz","34127","73.3","1","0","2","3","0","M","WT","1","0","1","0","Tum Patient 29","5-FU + RT","6.25","rectal tumor"
"GSM2325267","Patient 30 tumor sample","GSM2325267","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 30","age: 47.2","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -2.99","death due to tumor: 0","survival time (month): 13.12","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325267/suppl/GSM2325267_US22502691_252665211177_S01_GE1_107_Sep09_1_1.txt.gz","34127","47.2","1","0","3","3","-2.99","F","WT","1","1","1","1","Tum Patient 30","5-FU + Oxaliplatin + RT","13.12","rectal tumor"
"GSM2325268","Patient 31 tumor sample","GSM2325268","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 31","age: 72.7","gender: F","tissue: rectal tumor","kras mutation: G12S","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 16.21","death due to tumor: 0","survival time (month): 16.21","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325268/suppl/GSM2325268_US22502691_252665211067_S01_GE1_107_Sep09_1_3.txt.gz","34127","72.7","0","0","3","3","16.21","F","G12S","0","0","0","0","Tum Patient 31","5-FU + RT","16.21","rectal tumor"
"GSM2325269","Patient 32 tumor sample","GSM2325269","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 32","age: 38.8","gender: M","tissue: rectal tumor","kras mutation: G12C","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 6.38","death due to tumor: 0","survival time (month): 6.38","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325269/suppl/GSM2325269_US22502691_252665211158_S01_GE1_107_Sep09_1_1.txt.gz","34127","38.8","0","0","3","4","6.38","M","G12C","2","1","0","0","Tum Patient 32","5-FU + Oxaliplatin + RT","6.38","rectal tumor"
"GSM2325270","Patient 33 tumor sample","GSM2325270","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 33","age: 75.5","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 13.02","death due to tumor: 0","survival time (month): 13.02","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325270/suppl/GSM2325270_US22502691_252665211172_S01_GE1_107_Sep09_1_3.txt.gz","34127","75.5","0","0","3","3","13.02","M","WT","0","0","0","0","Tum Patient 33","5-FU + RT","13.02","rectal tumor"
"GSM2325271","Patient 34 tumor sample","GSM2325271","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 34","age: 80","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 2.96","death due to tumor: 0","survival time (month): 2.96","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325271/suppl/GSM2325271_US22502691_252665211191_S01_GE1_107_Sep09_1_3.txt.gz","34127","80","0","0","0","3","2.96","F","WT","0","1","0","0","Tum Patient 34","5-FU + Oxaliplatin + RT","2.96","rectal tumor"
"GSM2325272","Patient 35 tumor sample","GSM2325272","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 35","age: 60.9","gender: M","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 13.05","death due to tumor: 0","survival time (month): 13.05","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325272/suppl/GSM2325272_US22502691_252665211160_S01_GE1_107_Sep09_1_1.txt.gz","34127","60.9","0","0","3","3","13.05","M","G12D","1","1","0","0","Tum Patient 35","5-FU + RT","13.05","rectal tumor"
"GSM2325273","Patient 36 tumor sample","GSM2325273","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 36","age: 76.3","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 1.74","death due to tumor: 0","survival time (month): 1.74","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325273/suppl/GSM2325273_US22502691_252665211181_S01_GE1_107_Sep09_1_3.txt.gz","34127","76.3","0","0","3","3","1.74","M","WT","0","1","0","0","Tum Patient 36","5-FU + RT","1.74","rectal tumor"
"GSM2325274","Patient 37 tumor sample","GSM2325274","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 37","age: 49.5","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 12.59","death due to tumor: 0","survival time (month): 12.59","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325274/suppl/GSM2325274_US22502691_252665211141_S01_GE1_107_Sep09_1_1.txt.gz","34127","49.5","0","0","1","3","12.59","F","WT","0","0","0","0","Tum Patient 37","5-FU + Oxaliplatin + RT","12.59","rectal tumor"
"GSM2325275","Patient 38 tumor sample","GSM2325275","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 38","age: 49.9","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 11.57","death due to tumor: 0","survival time (month): 11.57","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325275/suppl/GSM2325275_US22502691_252665211224_S01_GE1_107_Sep09_1_3.txt.gz","34127","49.9","0","0","0","3","11.57","M","WT","0","0","0","0","Tum Patient 38","5-FU + Oxaliplatin + RT","11.57","rectal tumor"
"GSM2325276","Patient 39 tumor sample","GSM2325276","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 39","age: 57.6","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 9.83","death due to tumor: 0","survival time (month): 9.83","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325276/suppl/GSM2325276_US22502691_252665211220_S01_GE1_107_Sep09_1_1.txt.gz","34127","57.6","0","0","2","3","9.83","M","WT","0","1","0","0","Tum Patient 39","5-FU + RT","9.83","rectal tumor"
"GSM2325277","Patient 40 tumor sample","GSM2325277","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 40","age: 77.3","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 8.28","death due to tumor: 0","survival time (month): 8.28","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325277/suppl/GSM2325277_US22502691_252665211258_S01_GE1_107_Sep09_1_1.txt.gz","34127","77.3","0","0","2","3","8.28","M","WT","1","1","0","0","Tum Patient 40","5-FU + Oxaliplatin + RT","8.28","rectal tumor"
"GSM2325278","Patient 41 tumor sample","GSM2325278","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 41","age: 72.4","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 22.68","death due to tumor: 0","survival time (month): 22.68","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325278/suppl/GSM2325278_US22502691_252665211190_S01_GE1_107_Sep09_1_3.txt.gz","34127","72.4","1","0","3","3","22.68","M","WT","1","1","0","0","Tum Patient 41","5-FU + RT","22.68","rectal tumor"
"GSM2325279","Patient 42 tumor sample","GSM2325279","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 42","age: 76.3","gender: M","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 20.19","death due to tumor: 0","survival time (month): 20.19","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325279/suppl/GSM2325279_US22502691_252665211175_S01_GE1_107_Sep09_1_3.txt.gz","34127","76.3","0","0","2","3","20.19","M","G13D","0","1","0","0","Tum Patient 42","5-FU + RT","20.19","rectal tumor"
"GSM2325280","Patient 43 tumor sample","GSM2325280","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 43","age: 61.4","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 0","death due to tumor: 0","survival time (month): 0","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325280/suppl/GSM2325280_US22502691_252665211212_S01_GE1_107_Sep09_1_1.txt.gz","34127","61.4","0","0","3","3","0","M","WT","1","1","0","0","Tum Patient 43","5-FU + Oxaliplatin + RT","0","rectal tumor"
"GSM2325281","Patient 44 tumor sample","GSM2325281","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 44","age: 66.3","gender: F","tissue: rectal tumor","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 0","death due to tumor: 0","survival time (month): 0","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325281/suppl/GSM2325281_US22502691_252665211225_S01_GE1_107_Sep09_1_3.txt.gz","34127","66.3","0","0","3","3","0","F","NA","1","1","0","0","Tum Patient 44","5-FU + Oxaliplatin + RT","0","rectal tumor"
"GSM2325282","Patient 45 tumor sample","GSM2325282","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 45","age: 65.6","gender: M","tissue: rectal tumor","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 0","death due to tumor: 0","survival time (month): 0","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325282/suppl/GSM2325282_US22502691_252665211065_S01_GE1_107_Sep09_1_1.txt.gz","34127","65.6","0","0","0","3","0","M","NA","0","0","0","0","Tum Patient 45","5-FU + RT","0","rectal tumor"
"GSM2325283","Patient 46 tumor sample","GSM2325283","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 46","age: 68.4","gender: M","tissue: rectal tumor","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: NA","disease free time (month): NA","death due to tumor: NA","survival time (month): NA","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325283/suppl/GSM2325283_US22502691_252665211103_S01_GE1_107_Sep09_1_3.txt.gz","34127","68.4","NA","NA","3","3","NA","M","NA","1","1","0","0","Tum Patient 46","5-FU + RT","NA","rectal tumor"
"GSM2325284","Patient 47 tumor sample","GSM2325284","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 47","age: 78.9","gender: M","tissue: rectal tumor","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 2","lymph node metastasis before rct: 0","metastasis before rct: NA","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: NA","disease free time (month): NA","death due to tumor: NA","survival time (month): NA","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325284/suppl/GSM2325284_US22502691_252665211227_S01_GE1_107_Sep09_1_1.txt.gz","34127","78.9","NA","NA","0","2","NA","M","NA","0","0","0","NA","Tum Patient 47","5-FU + RT","NA","rectal tumor"
"GSM2325285","Patient 48 tumor sample","GSM2325285","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 48","age: 65.8","gender: M","tissue: rectal tumor","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: NA","disease free time (month): NA","death due to tumor: NA","survival time (month): NA","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325285/suppl/GSM2325285_US22502691_252665211207_S01_GE1_107_Sep09_1_3.txt.gz","34127","65.8","NA","NA","2","3","NA","M","NA","0","0","0","0","Tum Patient 48","5-FU + RT","NA","rectal tumor"
"GSM2325286","Patient 49 tumor sample","GSM2325286","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 49","age: 57.1","gender: F","tissue: rectal tumor","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: NA","disease free time (month): NA","death due to tumor: NA","survival time (month): NA","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325286/suppl/GSM2325286_US22502691_252665211066_S01_GE1_107_Sep09_1_3.txt.gz","34127","57.1","NA","NA","0","3","NA","F","NA","0","1","0","0","Tum Patient 49","5-FU + RT","NA","rectal tumor"
"GSM2325287","Patient 50 tumor sample","GSM2325287","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 50","age: 74.1","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 29.03","death due to tumor: 0","survival time (month): 29.03","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325287/suppl/GSM2325287_US22502691_252665211174_S01_GE1_107_Sep09_1_1.txt.gz","34127","74.1","1","0","1","3","29.03","M","WT","0","0","0","0","Tum Patient 50","5-FU + RT","29.03","rectal tumor"
"GSM2325288","Patient 51 tumor sample","GSM2325288","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 51","age: 48.2","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 1.78","death due to tumor: 0","survival time (month): 1.78","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325288/suppl/GSM2325288_US22502691_252665211204_S01_GE1_107_Sep09_1_3.txt.gz","34127","48.2","0","0","3","4","1.78","M","WT","2","1","0","0","Tum Patient 51","5-FU + Oxaliplatin + RT","1.78","rectal tumor"
"GSM2325289","Patient 52 tumor sample","GSM2325289","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 52","age: 56.3","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 0.69","death due to tumor: 0","survival time (month): 0.69","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325289/suppl/GSM2325289_US22502691_252665211223_S01_GE1_107_Sep09_1_1.txt.gz","34127","56.3","0","0","2","3","0.69","F","G12D","0","0","0","0","Tum Patient 52","5-FU + RT","0.69","rectal tumor"
"GSM2325290","Patient 53 tumor sample","GSM2325290","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 53","age: 61.9","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 151.17","death due to tumor: 0","survival time (month): 151.17","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325290/suppl/GSM2325290_US22502691_252665211224_S01_GE1_107_Sep09_1_1.txt.gz","34127","61.9","0","0","0","3","151.17","M","WT","0","0","0","0","Tum Patient 53","5-FU + RT","151.17","rectal tumor"
"GSM2325291","Patient 54 tumor sample","GSM2325291","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 54","age: 65.4","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 91","death due to tumor: 0","survival time (month): 91","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325291/suppl/GSM2325291_US22502691_252665211173_S01_GE1_107_Sep09_1_3.txt.gz","34127","65.4","0","0","2","3","91","M","WT","0","1","0","0","Tum Patient 54","5-FU + RT","91","rectal tumor"
"GSM2325292","Patient 55 tumor sample","GSM2325292","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 55","age: 49.2","gender: M","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 144.3","death due to tumor: 0","survival time (month): 144.3","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325292/suppl/GSM2325292_US22502691_252665211082_S01_GE1_107_Sep09_1_3.txt.gz","34127","49.2","0","0","1","3","144.3","M","G13D","0","0","0","0","Tum Patient 55","5-FU + RT","144.3","rectal tumor"
"GSM2325293","Patient 56 tumor sample","GSM2325293","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 56","age: 63.7","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 112.01","death due to tumor: 0","survival time (month): 112.01","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325293/suppl/GSM2325293_US22502691_252665211100_S01_GE1_107_Sep09_1_3.txt.gz","34127","63.7","0","0","1","3","112.01","M","WT","0","1","0","0","Tum Patient 56","5-FU + Oxaliplatin + RT","112.01","rectal tumor"
"GSM2325294","Patient 57 tumor sample","GSM2325294","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 57","age: 58.6","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 111.25","death due to tumor: 0","survival time (month): 111.25","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325294/suppl/GSM2325294_US22502691_252665211258_S01_GE1_107_Sep09_1_3.txt.gz","34127","58.6","0","0","3","3","111.25","F","G12D","0","0","0","0","Tum Patient 57","5-FU + Oxaliplatin + RT","111.25","rectal tumor"
"GSM2325295","Patient 58 tumor sample","GSM2325295","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 58","age: 66.4","gender: M","tissue: rectal tumor","kras mutation: Q61L","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 100.04","death due to tumor: 0","survival time (month): 100.04","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325295/suppl/GSM2325295_US22502691_252665211088_S01_GE1_107_Sep09_1_3.txt.gz","34127","66.4","0","0","0","3","100.04","M","Q61L","0","1","0","0","Tum Patient 58","5-FU + RT","100.04","rectal tumor"
"GSM2325296","Patient 59 tumor sample","GSM2325296","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 59","age: 62.1","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 3.16","death due to tumor: 0","survival time (month): 3.16","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325296/suppl/GSM2325296_US22502691_252665211183_S01_GE1_107_Sep09_1_3.txt.gz","34127","62.1","0","0","4","3","3.16","M","WT","2","1","0","0","Tum Patient 59","5-FU + Oxaliplatin + RT","3.16","rectal tumor"
"GSM2325297","Patient 60 tumor sample","GSM2325297","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 60","age: 57.4","gender: M","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 29.13","death due to tumor: 1","survival time (month): 70.72","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325297/suppl/GSM2325297_US22502691_252665211165_S01_GE1_107_Sep09_1_3.txt.gz","34127","57.4","1","1","2","3","29.13","M","G13D","0","0","0","0","Tum Patient 60","5-FU + Oxaliplatin + RT","70.72","rectal tumor"
"GSM2325298","Patient 61 tumor sample","GSM2325298","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 61","age: 48.4","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 112.24","death due to tumor: 0","survival time (month): 112.24","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325298/suppl/GSM2325298_US22502691_252665211186_S01_GE1_107_Sep09_1_1.txt.gz","34127","48.4","0","0","1","3","112.24","F","WT","0","1","0","0","Tum Patient 61","5-FU + Oxaliplatin + RT","112.24","rectal tumor"
"GSM2325299","Patient 62 tumor sample","GSM2325299","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 62","age: 71.2","gender: M","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 79.53","death due to tumor: 0","survival time (month): 79.53","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325299/suppl/GSM2325299_US22502691_252665211087_S01_GE1_107_Sep09_1_1.txt.gz","34127","71.2","0","0","2","3","79.53","M","G12D","0","0","0","0","Tum Patient 62","5-FU + Oxaliplatin + RT","79.53","rectal tumor"
"GSM2325300","Patient 63 tumor sample","GSM2325300","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 63","age: 71.2","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 109.84","death due to tumor: 0","survival time (month): 109.84","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325300/suppl/GSM2325300_US22502691_252665211188_S01_GE1_107_Sep09_1_1.txt.gz","34127","71.2","0","0","2","3","109.84","F","WT","0","0","0","0","Tum Patient 63","5-FU + Oxaliplatin + RT","109.84","rectal tumor"
"GSM2325301","Patient 64 tumor sample","GSM2325301","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 64","age: 52.7","gender: M","tissue: rectal tumor","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 62.93","death due to tumor: 1","survival time (month): 110.17","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325301/suppl/GSM2325301_US22502691_252665211193_S01_GE1_107_Sep09_1_3.txt.gz","34127","52.7","1","1","2","3","62.93","M","G12V","0","1","0","0","Tum Patient 64","5-FU + Oxaliplatin + RT","110.17","rectal tumor"
"GSM2325302","Patient 65 tumor sample","GSM2325302","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 65","age: 70.3","gender: M","tissue: rectal tumor","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 45.73","death due to tumor: 0","survival time (month): 45.73","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325302/suppl/GSM2325302_US22502691_252665211191_S01_GE1_107_Sep09_1_1.txt.gz","34127","70.3","0","0","3","3","45.73","M","G12V","1","1","0","0","Tum Patient 65","5-FU + RT","45.73","rectal tumor"
"GSM2325303","Patient 66 tumor sample","GSM2325303","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 66","age: 54","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 114.35","death due to tumor: 0","survival time (month): 114.35","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325303/suppl/GSM2325303_US22502691_252665211167_S01_GE1_107_Sep09_1_1.txt.gz","34127","54","0","0","1","3","114.35","F","G12D","0","1","0","0","Tum Patient 66","5-FU + Oxaliplatin + RT","114.35","rectal tumor"
"GSM2325304","Patient 67 tumor sample","GSM2325304","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 67","age: 53.7","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 58.92","death due to tumor: 1","survival time (month): 84.36","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325304/suppl/GSM2325304_US22502691_252665211175_S01_GE1_107_Sep09_1_1.txt.gz","34127","53.7","1","1","3","3","58.92","M","WT","0","0","0","0","Tum Patient 67","5-FU + RT","84.36","rectal tumor"
"GSM2325305","Patient 68 tumor sample","GSM2325305","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 68","age: 60","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 86.79","death due to tumor: 0","survival time (month): 86.79","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325305/suppl/GSM2325305_US22502691_252665211164_S01_GE1_107_Sep09_1_3.txt.gz","34127","60","0","0","3","3","86.79","M","WT","1","1","0","0","Tum Patient 68","5-FU + RT","86.79","rectal tumor"
"GSM2325306","Patient 69 tumor sample","GSM2325306","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 69","age: 68.2","gender: M","tissue: rectal tumor","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 93.96","death due to tumor: 0","survival time (month): 93.96","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325306/suppl/GSM2325306_US22502691_252665211105_S01_GE1_107_Sep09_1_1.txt.gz","34127","68.2","0","0","3","3","93.96","M","G12V","1","0","0","0","Tum Patient 69","5-FU + Oxaliplatin + RT","93.96","rectal tumor"
"GSM2325307","Patient 70 tumor sample","GSM2325307","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 70","age: 65.7","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 25.38","death due to tumor: 1","survival time (month): 51.52","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325307/suppl/GSM2325307_US22502691_252665211070_S01_GE1_107_Sep09_1_3.txt.gz","34127","65.7","1","1","3","3","25.38","M","WT","1","1","0","0","Tum Patient 70","5-FU + Oxaliplatin + RT","51.52","rectal tumor"
"GSM2325308","Patient 71 tumor sample","GSM2325308","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 71","age: 79.7","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 88.27","death due to tumor: 0","survival time (month): 88.27","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325308/suppl/GSM2325308_US22502691_252665211178_S01_GE1_107_Sep09_1_3.txt.gz","34127","79.7","0","0","2","3","88.27","M","WT","0","1","0","0","Tum Patient 71","5-FU + Oxaliplatin + RT","88.27","rectal tumor"
"GSM2325309","Patient 72 tumor sample","GSM2325309","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 72","age: 81.4","gender: F","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 82.98","death due to tumor: 0","survival time (month): 82.98","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325309/suppl/GSM2325309_US22502691_252665211180_S01_GE1_107_Sep09_1_1.txt.gz","34127","81.4","0","0","2","3","82.98","F","G13D","0","1","0","0","Tum Patient 72","5-FU + RT","82.98","rectal tumor"
"GSM2325310","Patient 73 tumor sample","GSM2325310","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 73","age: 66.3","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 71.31","death due to tumor: 0","survival time (month): 71.31","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325310/suppl/GSM2325310_US22502691_252665211077_S01_GE1_107_Sep09_1_1.txt.gz","34127","66.3","0","0","1","3","71.31","M","WT","0","1","0","0","Tum Patient 73","5-FU + Oxaliplatin + RT","71.31","rectal tumor"
"GSM2325311","Patient 74 tumor sample","GSM2325311","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 74","age: 59.3","gender: M","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 61.25","death due to tumor: 0","survival time (month): 61.25","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325311/suppl/GSM2325311_US22502691_252665211186_S01_GE1_107_Sep09_1_3.txt.gz","34127","59.3","0","0","2","3","61.25","M","G13D","0","1","0","0","Tum Patient 74","5-FU + RT","61.25","rectal tumor"
"GSM2325312","Patient 75 tumor sample","GSM2325312","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 75","age: 57.4","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 83.97","death due to tumor: 0","survival time (month): 83.97","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325312/suppl/GSM2325312_US22502691_252665211169_S01_GE1_107_Sep09_1_1.txt.gz","34127","57.4","0","0","2","3","83.97","M","WT","0","1","0","0","Tum Patient 75","5-FU + Oxaliplatin + RT","83.97","rectal tumor"
"GSM2325313","Patient 76 tumor sample","GSM2325313","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 76","age: 81.5","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 39.25","death due to tumor: 0","survival time (month): 39.25","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325313/suppl/GSM2325313_US22502691_252665211179_S01_GE1_107_Sep09_1_3.txt.gz","34127","81.5","0","0","3","3","39.25","M","WT","0","0","0","0","Tum Patient 76","5-FU + RT","39.25","rectal tumor"
"GSM2325314","Patient 77 tumor sample","GSM2325314","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 77","age: 62.3","gender: M","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 34.39","death due to tumor: 0","survival time (month): 34.39","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325314/suppl/GSM2325314_US22502691_252665211103_S01_GE1_107_Sep09_1_1.txt.gz","34127","62.3","0","0","2","3","34.39","M","G12D","0","0","0","0","Tum Patient 77","5-FU + RT","34.39","rectal tumor"
"GSM2325315","Patient 78 tumor sample","GSM2325315","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 78","age: 63.7","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 88.83","death due to tumor: 0","survival time (month): 88.83","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325315/suppl/GSM2325315_US22502691_252665211168_S01_GE1_107_Sep09_1_1.txt.gz","34127","63.7","0","0","3","3","88.83","F","G12D","0","1","0","0","Tum Patient 78","5-FU + RT","88.83","rectal tumor"
"GSM2325316","Patient 79 tumor sample","GSM2325316","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 79","age: 66.8","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 79.63","death due to tumor: 0","survival time (month): 79.63","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325316/suppl/GSM2325316_US22502691_252665211225_S01_GE1_107_Sep09_1_1.txt.gz","34127","66.8","0","0","0","3","79.63","F","WT","0","0","0","0","Tum Patient 79","5-FU + RT","79.63","rectal tumor"
"GSM2325317","Patient 80 tumor sample","GSM2325317","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 80","age: 71.5","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 73.48","death due to tumor: 0","survival time (month): 82.82","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325317/suppl/GSM2325317_US22502691_252665211166_S01_GE1_107_Sep09_1_3.txt.gz","34127","71.5","1","0","3","4","73.48","F","WT","1","1","0","0","Tum Patient 80","5-FU + RT","82.82","rectal tumor"
"GSM2325318","Patient 81 tumor sample","GSM2325318","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 81","age: 76.8","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 77.85","death due to tumor: 0","survival time (month): 77.85","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325318/suppl/GSM2325318_US22502691_252665211212_S01_GE1_107_Sep09_1_3.txt.gz","34127","76.8","0","0","3","3","77.85","M","WT","0","1","0","0","Tum Patient 81","5-FU + RT","77.85","rectal tumor"
"GSM2325319","Patient 82 tumor sample","GSM2325319","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 82","age: 76.5","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 75.48","death due to tumor: 0","survival time (month): 75.48","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325319/suppl/GSM2325319_US22502691_252665211163_S01_GE1_107_Sep09_1_1.txt.gz","34127","76.5","0","0","0","3","75.48","F","WT","0","0","0","0","Tum Patient 82","5-FU + RT","75.48","rectal tumor"
"GSM2325320","Patient 83 tumor sample","GSM2325320","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 83","age: 58.3","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 96.03","death due to tumor: 0","survival time (month): 96.03","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325320/suppl/GSM2325320_US22502691_252665211138_S01_GE1_107_Sep09_1_1.txt.gz","34127","58.3","0","0","3","3","96.03","F","WT","2","1","0","0","Tum Patient 83","5-FU + RT","96.03","rectal tumor"
"GSM2325321","Patient 84 tumor sample","GSM2325321","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 84","age: 76.7","gender: M","tissue: rectal tumor","kras mutation: G12A","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 98.7","death due to tumor: 0","survival time (month): 98.7","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325321/suppl/GSM2325321_US22502691_252665211156_S01_GE1_107_Sep09_1_1.txt.gz","34127","76.7","0","0","3","3","98.7","M","G12A","1","0","0","0","Tum Patient 84","5-FU + RT","98.7","rectal tumor"
"GSM2325322","Patient 85 tumor sample","GSM2325322","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 85","age: 62.6","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 34.06","death due to tumor: 1","survival time (month): 79.5","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325322/suppl/GSM2325322_US22502691_252665211210_S01_GE1_107_Sep09_1_3.txt.gz","34127","62.6","1","1","4","3","34.06","F","G12D","0","1","0","0","Tum Patient 85","5-FU + RT","79.5","rectal tumor"
"GSM2325323","Patient 86 tumor sample","GSM2325323","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 86","age: 51.2","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 76.87","death due to tumor: 0","survival time (month): 76.87","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325323/suppl/GSM2325323_US22502691_252665211192_S01_GE1_107_Sep09_1_1.txt.gz","34127","51.2","0","0","1","3","76.87","M","WT","0","0","0","0","Tum Patient 86","5-FU + RT","76.87","rectal tumor"
"GSM2325324","Patient 87 tumor sample","GSM2325324","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 87","age: 67.8","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 29.82","death due to tumor: 0","survival time (month): 29.82","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325324/suppl/GSM2325324_US22502691_252665211214_S01_GE1_107_Sep09_1_1.txt.gz","34127","67.8","0","0","3","3","29.82","F","WT","1","1","0","0","Tum Patient 87","5-FU + RT","29.82","rectal tumor"
"GSM2325325","Patient 88 tumor sample","GSM2325325","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 88","age: 63.4","gender: M","tissue: rectal tumor","kras mutation: G12A","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 90.02","death due to tumor: 0","survival time (month): 90.02","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325325/suppl/GSM2325325_US22502691_252665211189_S01_GE1_107_Sep09_1_1.txt.gz","34127","63.4","0","0","2","3","90.02","M","G12A","0","1","0","0","Tum Patient 88","5-FU + RT","90.02","rectal tumor"
"GSM2325326","Patient 89 tumor sample","GSM2325326","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 89","age: 76.3","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 71.61","death due to tumor: 0","survival time (month): 71.61","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325326/suppl/GSM2325326_US22502691_252665211216_S01_GE1_107_Sep09_1_3.txt.gz","34127","76.3","0","0","1","3","71.61","F","G12D","0","0","0","0","Tum Patient 89","5-FU + Oxaliplatin + RT","71.61","rectal tumor"
"GSM2325327","Patient 90 tumor sample","GSM2325327","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 90","age: 41.8","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 94.26","death due to tumor: 0","survival time (month): 94.26","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325327/suppl/GSM2325327_US22502691_252665211152_S01_GE1_107_Sep09_1_1.txt.gz","34127","41.8","0","0","2","3","94.26","F","G12D","1","1","0","0","Tum Patient 90","5-FU + Oxaliplatin + RT","94.26","rectal tumor"
"GSM2325328","Patient 91 tumor sample","GSM2325328","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 91","age: 58.1","gender: M","tissue: rectal tumor","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 91.63","death due to tumor: 0","survival time (month): 91.63","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325328/suppl/GSM2325328_US22502691_252665211090_S01_GE1_107_Sep09_1_1.txt.gz","34127","58.1","0","0","3","3","91.63","M","G12V","0","0","0","0","Tum Patient 91","5-FU + Oxaliplatin + RT","91.63","rectal tumor"
"GSM2325329","Patient 92 tumor sample","GSM2325329","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 92","age: 65.8","gender: M","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 60.79","death due to tumor: 0","survival time (month): 60.79","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325329/suppl/GSM2325329_US22502691_252665211184_S01_GE1_107_Sep09_1_1.txt.gz","34127","65.8","0","0","2","3","60.79","M","G13D","0","1","0","0","Tum Patient 92","5-FU + Oxaliplatin + RT","60.79","rectal tumor"
"GSM2325330","Patient 93 tumor sample","GSM2325330","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 93","age: 59.5","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 63.52","death due to tumor: 0","survival time (month): 63.52","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325330/suppl/GSM2325330_US22502691_252665211157_S01_GE1_107_Sep09_1_3.txt.gz","34127","59.5","0","0","0","3","63.52","F","G12D","0","1","0","0","Tum Patient 93","5-FU + Oxaliplatin + RT","63.52","rectal tumor"
"GSM2325331","Patient 94 tumor sample","GSM2325331","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 94","age: 53.7","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 27.12","death due to tumor: 1","survival time (month): 33.6","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325331/suppl/GSM2325331_US22502691_252665211165_S01_GE1_107_Sep09_1_1.txt.gz","34127","53.7","1","1","3","3","27.12","M","WT","1","1","0","0","Tum Patient 94","5-FU + Oxaliplatin + RT","33.6","rectal tumor"
"GSM2325332","Patient 95 tumor sample","GSM2325332","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 95","age: 56.9","gender: M","tissue: rectal tumor","kras mutation: A146T","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 87.35","death due to tumor: 0","survival time (month): 87.35","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325332/suppl/GSM2325332_US22502691_252665211087_S01_GE1_107_Sep09_1_3.txt.gz","34127","56.9","0","0","0","3","87.35","M","A146T","0","1","0","0","Tum Patient 95","5-FU + RT","87.35","rectal tumor"
"GSM2325333","Patient 96 tumor sample","GSM2325333","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 96","age: 60.7","gender: M","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 2","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 109.32","death due to tumor: 0","survival time (month): 109.32","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325333/suppl/GSM2325333_US22502691_252665211077_S01_GE1_107_Sep09_1_3.txt.gz","34127","60.7","0","0","0","2","109.32","M","G13D","0","1","0","0","Tum Patient 96","5-FU + RT","109.32","rectal tumor"
"GSM2325334","Patient 97 tumor sample","GSM2325334","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 97","age: 64.1","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 46.62","death due to tumor: 1","survival time (month): 73.48","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325334/suppl/GSM2325334_US22502691_252665211217_S01_GE1_107_Sep09_1_3.txt.gz","34127","64.1","1","1","4","3","46.62","F","WT","0","0","0","0","Tum Patient 97","5-FU + RT","73.48","rectal tumor"
"GSM2325335","Patient 98 tumor sample","GSM2325335","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 98","age: 55.5","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -3.78","death due to tumor: 1","survival time (month): 25.51","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325335/suppl/GSM2325335_US22502691_252665211187_S01_GE1_107_Sep09_1_1.txt.gz","34127","55.5","1","1","3","3","-3.78","M","WT","1","1","1","0","Tum Patient 98","5-FU + RT","25.51","rectal tumor"
"GSM2325336","Patient 99 tumor sample","GSM2325336","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 99","age: 50","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 12.62","death due to tumor: 0","survival time (month): 105.14","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325336/suppl/GSM2325336_US22502691_252665211159_S01_GE1_107_Sep09_1_3.txt.gz","34127","50","1","0","2","3","12.62","M","WT","0","0","0","0","Tum Patient 99","5-FU + RT","105.14","rectal tumor"
"GSM2325337","Patient 100 tumor sample","GSM2325337","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 100","age: 35.7","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 68.65","death due to tumor: 1","survival time (month): 91.53","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325337/suppl/GSM2325337_US22502691_252665211170_S01_GE1_107_Sep09_1_1.txt.gz","34127","35.7","1","1","3","3","68.65","M","WT","1","1","0","0","Tum Patient 100","5-FU + RT","91.53","rectal tumor"
"GSM2325338","Patient 101 tumor sample","GSM2325338","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 101","age: 77.8","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 91.13","death due to tumor: 0","survival time (month): 91.13","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325338/suppl/GSM2325338_US22502691_252665211161_S01_GE1_107_Sep09_1_3.txt.gz","34127","77.8","0","0","3","3","91.13","M","WT","1","0","0","0","Tum Patient 101","5-FU + RT","91.13","rectal tumor"
"GSM2325339","Patient 102 tumor sample","GSM2325339","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 102","age: 65.1","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 79.79","death due to tumor: 0","survival time (month): 79.79","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325339/suppl/GSM2325339_US22502691_252665211188_S01_GE1_107_Sep09_1_3.txt.gz","34127","65.1","0","0","2","3","79.79","M","WT","0","1","0","0","Tum Patient 102","5-FU + RT","79.79","rectal tumor"
"GSM2325340","Patient 103 tumor sample","GSM2325340","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 103","age: 74.6","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 18.64","death due to tumor: 1","survival time (month): 24.39","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325340/suppl/GSM2325340_US22502691_252665211220_S01_GE1_107_Sep09_1_3.txt.gz","34127","74.6","1","1","3","3","18.64","F","G12D","0","1","0","0","Tum Patient 103","5-FU + Oxaliplatin + RT","24.39","rectal tumor"
"GSM2325341","Patient 104 tumor sample","GSM2325341","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 104","age: 63","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 100.7","death due to tumor: 0","survival time (month): 100.7","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325341/suppl/GSM2325341_US22502691_252665211185_S01_GE1_107_Sep09_1_3.txt.gz","34127","63","0","0","2","3","100.7","M","WT","0","1","0","0","Tum Patient 104","5-FU + Oxaliplatin + RT","100.7","rectal tumor"
"GSM2325342","Patient 105 tumor sample","GSM2325342","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 105","age: 73.3","gender: M","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 85.84","death due to tumor: 0","survival time (month): 85.84","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325342/suppl/GSM2325342_US22502691_252665211163_S01_GE1_107_Sep09_1_3.txt.gz","34127","73.3","0","0","3","3","85.84","M","G13D","0","1","0","0","Tum Patient 105","5-FU + Oxaliplatin + RT","85.84","rectal tumor"
"GSM2325343","Patient 106 tumor sample","GSM2325343","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 106","age: 73.3","gender: M","tissue: rectal tumor","kras mutation: G12A","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 75.72","death due to tumor: 0","survival time (month): 75.72","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325343/suppl/GSM2325343_US22502691_252665211089_S01_GE1_107_Sep09_1_3.txt.gz","34127","73.3","0","0","3","3","75.72","M","G12A","0","1","0","0","Tum Patient 106","5-FU + RT","75.72","rectal tumor"
"GSM2325344","Patient 107 tumor sample","GSM2325344","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 107","age: 54.8","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 33.11","death due to tumor: 0","survival time (month): 78.84","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325344/suppl/GSM2325344_US22502691_252665211105_S01_GE1_107_Sep09_1_3.txt.gz","34127","54.8","1","0","1","3","33.11","M","WT","2","1","0","0","Tum Patient 107","5-FU + RT","78.84","rectal tumor"
"GSM2325345","Patient 108 tumor sample","GSM2325345","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 108","age: 61.5","gender: M","tissue: rectal tumor","kras mutation: A146T","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 2.4","death due to tumor: 0","survival time (month): 2.4","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325345/suppl/GSM2325345_US22502691_252665211156_S01_GE1_107_Sep09_1_3.txt.gz","34127","61.5","0","0","3","3","2.4","M","A146T","1","1","0","0","Tum Patient 108","5-FU + Oxaliplatin + RT","2.4","rectal tumor"
"GSM2325346","Patient 109 tumor sample","GSM2325346","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 109","age: 63.2","gender: F","tissue: rectal tumor","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 14.99","death due to tumor: 1","survival time (month): 29.46","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325346/suppl/GSM2325346_US22502691_252665211221_S01_GE1_107_Sep09_1_3.txt.gz","34127","63.2","1","1","3","3","14.99","F","G12V","0","1","0","0","Tum Patient 109","5-FU + RT","29.46","rectal tumor"
"GSM2325347","Patient 110 tumor sample","GSM2325347","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 110","age: 63.9","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 23.05","death due to tumor: 0","survival time (month): 23.05","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325347/suppl/GSM2325347_US22502691_252665211067_S01_GE1_107_Sep09_1_1.txt.gz","34127","63.9","0","0","2","3","23.05","M","WT","0","1","0","0","Tum Patient 110","5-FU + Oxaliplatin + RT","23.05","rectal tumor"
"GSM2325348","Patient 111 tumor sample","GSM2325348","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 111","age: 75.5","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 12.82","death due to tumor: 1","survival time (month): 20.32","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325348/suppl/GSM2325348_US22502691_252665211226_S01_GE1_107_Sep09_1_3.txt.gz","34127","75.5","1","1","1","3","12.82","M","WT","0","0","0","0","Tum Patient 111","5-FU + Oxaliplatin + RT","20.32","rectal tumor"
"GSM2325349","Patient 112 tumor sample","GSM2325349","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 112","age: 68.3","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 2","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 95.74","death due to tumor: 0","survival time (month): 95.74","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325349/suppl/GSM2325349_US22502691_252665211099_S01_GE1_107_Sep09_1_3.txt.gz","34127","68.3","0","0","0","2","95.74","F","WT","0","1","0","0","Tum Patient 112","5-FU + Oxaliplatin + RT","95.74","rectal tumor"
"GSM2325350","Patient 113 tumor sample","GSM2325350","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 113","age: 51.1","gender: F","tissue: rectal tumor","kras mutation: Q61L","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 18.18","death due to tumor: 0","survival time (month): 36.33","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325350/suppl/GSM2325350_US22502691_252665211178_S01_GE1_107_Sep09_1_1.txt.gz","34127","51.1","1","0","4","3","18.18","F","Q61L","0","1","0","0","Tum Patient 113","5-FU + Oxaliplatin + RT","36.33","rectal tumor"
"GSM2325351","Patient 114 tumor sample","GSM2325351","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 114","age: 46.3","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 96.13","death due to tumor: 0","survival time (month): 96.13","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325351/suppl/GSM2325351_US22502691_252665211180_S01_GE1_107_Sep09_1_3.txt.gz","34127","46.3","0","0","0","3","96.13","F","WT","0","1","0","0","Tum Patient 114","5-FU + Oxaliplatin + RT","96.13","rectal tumor"
"GSM2325352","Patient 115 tumor sample","GSM2325352","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 115","age: 59.4","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 73.38","death due to tumor: 0","survival time (month): 73.38","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325352/suppl/GSM2325352_US22502691_252665211075_S01_GE1_107_Sep09_1_1.txt.gz","34127","59.4","0","0","3","3","73.38","F","WT","1","1","0","0","Tum Patient 115","5-FU + Oxaliplatin + RT","73.38","rectal tumor"
"GSM2325353","Patient 116 tumor sample","GSM2325353","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 116","age: 70.9","gender: F","tissue: rectal tumor","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 33.14","death due to tumor: 0","survival time (month): 45.57","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325353/suppl/GSM2325353_US22502691_252665211083_S01_GE1_107_Sep09_1_1.txt.gz","34127","70.9","1","0","3","3","33.14","F","G12V","0","1","0","0","Tum Patient 116","5-FU + RT","45.57","rectal tumor"
"GSM2325354","Patient 117 tumor sample","GSM2325354","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 117","age: 59.8","gender: M","tissue: rectal tumor","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 64.87","death due to tumor: 0","survival time (month): 64.87","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325354/suppl/GSM2325354_US22502691_252665211167_S01_GE1_107_Sep09_1_3.txt.gz","34127","59.8","0","0","3","3","64.87","M","G12V","0","1","0","0","Tum Patient 117","5-FU + RT","64.87","rectal tumor"
"GSM2325355","Patient 118 tumor sample","GSM2325355","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 118","age: 81.1","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 44.61","death due to tumor: 0","survival time (month): 44.61","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325355/suppl/GSM2325355_US22502691_252665211174_S01_GE1_107_Sep09_1_3.txt.gz","34127","81.1","0","0","3","3","44.61","M","WT","2","1","0","0","Tum Patient 118","5-FU + RT","44.61","rectal tumor"
"GSM2325356","Patient 119 tumor sample","GSM2325356","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 119","age: 73","gender: F","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 70.19","death due to tumor: 0","survival time (month): 70.19","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325356/suppl/GSM2325356_US22502691_252665211215_S01_GE1_107_Sep09_1_3.txt.gz","34127","73","0","0","3","3","70.19","F","G13D","0","1","0","0","Tum Patient 119","5-FU + RT","70.19","rectal tumor"
"GSM2325357","Patient 120 tumor sample","GSM2325357","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 120","age: 70.9","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 71.74","death due to tumor: 0","survival time (month): 71.74","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325357/suppl/GSM2325357_US22502691_252665211211_S01_GE1_107_Sep09_1_3.txt.gz","34127","70.9","0","0","3","3","71.74","M","WT","0","0","0","0","Tum Patient 120","5-FU + Oxaliplatin + RT","71.74","rectal tumor"
"GSM2325358","Patient 121 tumor sample","GSM2325358","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 121","age: 63.8","gender: M","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 24.99","death due to tumor: 1","survival time (month): 49.91","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325358/suppl/GSM2325358_US22502691_252665211176_S01_GE1_107_Sep09_1_3.txt.gz","34127","63.8","1","1","4","4","24.99","M","G12D","1","1","0","0","Tum Patient 121","5-FU + Oxaliplatin + RT","49.91","rectal tumor"
"GSM2325359","Patient 122 tumor sample","GSM2325359","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 122","age: 63.7","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 63.42","death due to tumor: 0","survival time (month): 63.42","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325359/suppl/GSM2325359_US22502691_252665211190_S01_GE1_107_Sep09_1_1.txt.gz","34127","63.7","0","0","3","3","63.42","M","WT","0","0","0","0","Tum Patient 122","5-FU + RT","63.42","rectal tumor"
"GSM2325360","Patient 123 tumor sample","GSM2325360","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 123","age: 72.3","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 0","death due to tumor: 0","survival time (month): 91.43","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325360/suppl/GSM2325360_US22502691_252665211210_S01_GE1_107_Sep09_1_1.txt.gz","34127","72.3","1","0","2","3","0","M","WT","0","1","1","1","Tum Patient 123","5-FU + RT","91.43","rectal tumor"
"GSM2325361","Patient 124 tumor sample","GSM2325361","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 124","age: 51.9","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -3.19","death due to tumor: 1","survival time (month): 8.81","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325361/suppl/GSM2325361_US22502691_252665211090_S01_GE1_107_Sep09_1_3.txt.gz","34127","51.9","1","1","3","3","-3.19","M","WT","0","1","1","1","Tum Patient 124","5-FU + Oxaliplatin + RT","8.81","rectal tumor"
"GSM2325362","Patient 125 tumor sample","GSM2325362","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 125","age: 69.6","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 63.72","death due to tumor: 0","survival time (month): 63.72","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325362/suppl/GSM2325362_US22502691_252665211202_S01_GE1_107_Sep09_1_1.txt.gz","34127","69.6","0","0","0","3","63.72","F","WT","0","1","0","0","Tum Patient 125","5-FU + RT","63.72","rectal tumor"
"GSM2325363","Patient 126 tumor sample","GSM2325363","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 126","age: 65.1","gender: F","tissue: rectal tumor","kras mutation: G12C","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 60.53","death due to tumor: 0","survival time (month): 60.53","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325363/suppl/GSM2325363_US22502691_252665211202_S01_GE1_107_Sep09_1_3.txt.gz","34127","65.1","0","0","4","3","60.53","F","G12C","0","1","0","0","Tum Patient 126","5-FU + Oxaliplatin + RT","60.53","rectal tumor"
"GSM2325364","Patient 127 tumor sample","GSM2325364","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 127","age: 60.2","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + Cetuximab + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 73.84","death due to tumor: 0","survival time (month): 73.84","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325364/suppl/GSM2325364_US22502691_252665211211_S01_GE1_107_Sep09_1_1.txt.gz","34127","60.2","0","0","0","3","73.84","M","WT","0","1","0","0","Tum Patient 127","5-FU + Oxaliplatin + Cetuximab + RT","73.84","rectal tumor"
"GSM2325365","Patient 128 tumor sample","GSM2325365","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 128","age: 56.3","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 65.72","death due to tumor: 0","survival time (month): 65.72","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325365/suppl/GSM2325365_US22502691_252665211177_S01_GE1_107_Sep09_1_3.txt.gz","34127","56.3","0","0","3","3","65.72","F","G12D","1","1","0","0","Tum Patient 128","5-FU + RT","65.72","rectal tumor"
"GSM2325366","Patient 129 tumor sample","GSM2325366","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 129","age: 66.2","gender: M","tissue: rectal tumor","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 60.46","death due to tumor: 0","survival time (month): 60.46","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325366/suppl/GSM2325366_US22502691_252665211209_S01_GE1_107_Sep09_1_3.txt.gz","34127","66.2","0","0","3","3","60.46","M","NA","0","1","0","0","Tum Patient 129","5-FU + Oxaliplatin + RT","60.46","rectal tumor"
"GSM2325367","Patient 130 tumor sample","GSM2325367","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 130","age: 79.9","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 72.43","death due to tumor: 0","survival time (month): 72.43","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325367/suppl/GSM2325367_US22502691_252665211074_S01_GE1_107_Sep09_1_3.txt.gz","34127","79.9","0","0","3","3","72.43","M","WT","0","1","0","0","Tum Patient 130","5-FU + Oxaliplatin + RT","72.43","rectal tumor"
"GSM2325368","Patient 131 tumor sample","GSM2325368","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 131","age: 67.5","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 68.48","death due to tumor: 0","survival time (month): 68.48","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325368/suppl/GSM2325368_US22502691_252665211168_S01_GE1_107_Sep09_1_3.txt.gz","34127","67.5","0","0","3","3","68.48","M","WT","0","1","0","0","Tum Patient 131","5-FU + Oxaliplatin + RT","68.48","rectal tumor"
"GSM2325369","Patient 132 tumor sample","GSM2325369","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 132","age: 60.6","gender: M","tissue: rectal tumor","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + Cetuximab + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 63.09","death due to tumor: 0","survival time (month): 63.09","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325369/suppl/GSM2325369_US22502691_252665211098_S01_GE1_107_Sep09_1_3.txt.gz","34127","60.6","0","0","2","3","63.09","M","G12V","0","0","0","0","Tum Patient 132","5-FU + Oxaliplatin + Cetuximab + RT","63.09","rectal tumor"
"GSM2325370","Patient 133 tumor sample","GSM2325370","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 133","age: 51.8","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + Cetuximab + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 71.24","death due to tumor: 0","survival time (month): 71.24","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325370/suppl/GSM2325370_US22502691_252665211205_S01_GE1_107_Sep09_1_3.txt.gz","34127","51.8","0","0","2","3","71.24","F","WT","0","1","0","0","Tum Patient 133","5-FU + Oxaliplatin + Cetuximab + RT","71.24","rectal tumor"
"GSM2325371","Patient 134 tumor sample","GSM2325371","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 134","age: 57.5","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + Cetuximab + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: NA","lymph node metastasis after rct: 2","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 0","death due to tumor: 1","survival time (month): 3.32","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325371/suppl/GSM2325371_US22502691_252665211194_S01_GE1_107_Sep09_1_1.txt.gz","34127","57.5","1","1","NA","3","0","M","WT","2","1","1","0","Tum Patient 134","5-FU + Oxaliplatin + Cetuximab + RT","3.32","rectal tumor"
"GSM2325372","Patient 135 tumor sample","GSM2325372","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 135","age: 54.8","gender: M","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 72.43","death due to tumor: 0","survival time (month): 72.43","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325372/suppl/GSM2325372_US22502691_252665211086_S01_GE1_107_Sep09_1_3.txt.gz","34127","54.8","0","0","1","3","72.43","M","G12D","0","0","0","0","Tum Patient 135","5-FU + Oxaliplatin + RT","72.43","rectal tumor"
"GSM2325373","Patient 136 tumor sample","GSM2325373","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 136","age: 73.7","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 24.13","death due to tumor: 0","survival time (month): 61.41","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325373/suppl/GSM2325373_US22502691_252665211162_S01_GE1_107_Sep09_1_1.txt.gz","34127","73.7","1","0","3","3","24.13","F","G12D","0","1","0","0","Tum Patient 136","5-FU + RT","61.41","rectal tumor"
"GSM2325374","Patient 137 tumor sample","GSM2325374","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 137","age: 73.9","gender: F","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 23.01","death due to tumor: 1","survival time (month): 42.97","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325374/suppl/GSM2325374_US22502691_252665211181_S01_GE1_107_Sep09_1_1.txt.gz","34127","73.9","1","1","3","3","23.01","F","G13D","1","1","0","0","Tum Patient 137","5-FU + RT","42.97","rectal tumor"
"GSM2325375","Patient 138 tumor sample","GSM2325375","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 138","age: 50.5","gender: F","tissue: rectal tumor","kras mutation: A146T","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 42.54","death due to tumor: 0","survival time (month): 42.54","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325375/suppl/GSM2325375_US22502691_252665211194_S01_GE1_107_Sep09_1_3.txt.gz","34127","50.5","0","0","3","3","42.54","F","A146T","0","1","0","0","Tum Patient 138","5-FU + RT","42.54","rectal tumor"
"GSM2325376","Patient 139 tumor sample","GSM2325376","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 139","age: 77","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 82.88","death due to tumor: 0","survival time (month): 82.88","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325376/suppl/GSM2325376_US22502691_252665211083_S01_GE1_107_Sep09_1_3.txt.gz","34127","77","0","0","3","3","82.88","F","WT","1","1","0","0","Tum Patient 139","5-FU + Oxaliplatin + RT","82.88","rectal tumor"
"GSM2325377","Patient 140 tumor sample","GSM2325377","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 140","age: 41.8","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 71.8","death due to tumor: 0","survival time (month): 71.8","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325377/suppl/GSM2325377_US22502691_252665211187_S01_GE1_107_Sep09_1_3.txt.gz","34127","41.8","0","0","2","3","71.8","F","G12D","0","1","0","0","Tum Patient 140","5-FU + Oxaliplatin + RT","71.8","rectal tumor"
"GSM2325378","Patient 141 tumor sample","GSM2325378","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 141","age: 73.1","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 63.48","death due to tumor: 0","survival time (month): 63.48","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325378/suppl/GSM2325378_US22502691_252665211182_S01_GE1_107_Sep09_1_3.txt.gz","34127","73.1","0","0","0","3","63.48","M","WT","0","1","0","0","Tum Patient 141","5-FU + RT","63.48","rectal tumor"
"GSM2325379","Patient 142 tumor sample","GSM2325379","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 142","age: 67","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 78.71","death due to tumor: 0","survival time (month): 78.71","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325379/suppl/GSM2325379_US22502691_252665211141_S01_GE1_107_Sep09_1_3.txt.gz","34127","67","0","0","0","4","78.71","M","WT","0","1","0","0","Tum Patient 142","5-FU + RT","78.71","rectal tumor"
"GSM2325380","Patient 143 tumor sample","GSM2325380","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 143","age: 61.9","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 73.38","death due to tumor: 0","survival time (month): 73.38","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325380/suppl/GSM2325380_US22502691_252665211259_S01_GE1_107_Sep09_1_1.txt.gz","34127","61.9","0","0","0","3","73.38","M","WT","0","1","0","0","Tum Patient 143","5-FU + Oxaliplatin + RT","73.38","rectal tumor"
"GSM2325381","Patient 144 tumor sample","GSM2325381","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 144","age: 42","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 77.59","death due to tumor: 0","survival time (month): 77.59","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325381/suppl/GSM2325381_US22502691_252665211169_S01_GE1_107_Sep09_1_3.txt.gz","34127","42","0","0","0","3","77.59","M","WT","0","0","0","0","Tum Patient 144","5-FU + Oxaliplatin + RT","77.59","rectal tumor"
"GSM2325382","Patient 145 tumor sample","GSM2325382","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 145","age: 68.7","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 40.67","death due to tumor: 0","survival time (month): 40.67","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325382/suppl/GSM2325382_US22502691_252665211228_S01_GE1_107_Sep09_1_3.txt.gz","34127","68.7","0","0","2","3","40.67","M","WT","0","1","0","0","Tum Patient 145","5-FU + Oxaliplatin + RT","40.67","rectal tumor"
"GSM2325383","Patient 146 tumor sample","GSM2325383","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 146","age: 59.4","gender: F","tissue: rectal tumor","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 0","death due to tumor: 1","survival time (month): 35.8","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325383/suppl/GSM2325383_US22502691_252665211071_S01_GE1_107_Sep09_1_1.txt.gz","34127","59.4","1","1","3","3","0","F","G12V","2","1","1","1","Tum Patient 146","5-FU + Oxaliplatin + RT","35.8","rectal tumor"
"GSM2325384","Patient 147 tumor sample","GSM2325384","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 147","age: 78.8","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 64.5","death due to tumor: 0","survival time (month): 64.5","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325384/suppl/GSM2325384_US22502691_252665211173_S01_GE1_107_Sep09_1_1.txt.gz","34127","78.8","0","0","3","3","64.5","F","WT","0","1","0","0","Tum Patient 147","5-FU + Oxaliplatin + RT","64.5","rectal tumor"
"GSM2325385","Patient 148 tumor sample","GSM2325385","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 148","age: 57.3","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 72.56","death due to tumor: 0","survival time (month): 72.56","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325385/suppl/GSM2325385_US22502691_252665211221_S01_GE1_107_Sep09_1_1.txt.gz","34127","57.3","0","0","0","3","72.56","M","WT","0","1","0","0","Tum Patient 148","5-FU + Oxaliplatin + RT","72.56","rectal tumor"
"GSM2325386","Patient 149 tumor sample","GSM2325386","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 149","age: 63.7","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 74.33","death due to tumor: 0","survival time (month): 74.33","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325386/suppl/GSM2325386_US22502691_252665211218_S01_GE1_107_Sep09_1_3.txt.gz","34127","63.7","0","0","3","3","74.33","F","WT","0","1","0","0","Tum Patient 149","5-FU + Oxaliplatin + RT","74.33","rectal tumor"
"GSM2325387","Patient 150 tumor sample","GSM2325387","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 150","age: 60.7","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 27.32","death due to tumor: 1","survival time (month): 40.83","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325387/suppl/GSM2325387_US22502691_252665211101_S01_GE1_107_Sep09_1_1.txt.gz","34127","60.7","1","1","3","3","27.32","M","WT","0","1","0","0","Tum Patient 150","5-FU + Oxaliplatin + RT","40.83","rectal tumor"
"GSM2325388","Patient 151 tumor sample","GSM2325388","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 151","age: 62.5","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 72.1","death due to tumor: 0","survival time (month): 72.1","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325388/suppl/GSM2325388_US22502691_252665211219_S01_GE1_107_Sep09_1_1.txt.gz","34127","62.5","0","0","2","3","72.1","M","WT","0","1","0","0","Tum Patient 151","5-FU + RT","72.1","rectal tumor"
"GSM2325389","Patient 152 tumor sample","GSM2325389","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 152","age: 51.7","gender: F","tissue: rectal tumor","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 69.04","death due to tumor: 0","survival time (month): 69.04","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325389/suppl/GSM2325389_US22502691_252665211152_S01_GE1_107_Sep09_1_3.txt.gz","34127","51.7","0","0","3","3","69.04","F","G12V","1","1","0","0","Tum Patient 152","5-FU + Oxaliplatin + RT","69.04","rectal tumor"
"GSM2325390","Patient 153 tumor sample","GSM2325390","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 153","age: 56.5","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 70.09","death due to tumor: 0","survival time (month): 70.09","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325390/suppl/GSM2325390_US22502691_252665211164_S01_GE1_107_Sep09_1_1.txt.gz","34127","56.5","0","0","3","3","70.09","F","WT","0","1","0","0","Tum Patient 153","5-FU + Oxaliplatin + RT","70.09","rectal tumor"
"GSM2325391","Patient 154 tumor sample","GSM2325391","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 154","age: 74.9","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 2.2","death due to tumor: 0","survival time (month): 2.2","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325391/suppl/GSM2325391_US22502691_252665211216_S01_GE1_107_Sep09_1_1.txt.gz","34127","74.9","0","0","2","3","2.2","M","WT","0","1","0","0","Tum Patient 154","5-FU + RT","2.2","rectal tumor"
"GSM2325392","Patient 155 tumor sample","GSM2325392","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 155","age: 61.5","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 2","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 71.54","death due to tumor: 0","survival time (month): 71.54","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325392/suppl/GSM2325392_US22502691_252665211158_S01_GE1_107_Sep09_1_3.txt.gz","34127","61.5","0","0","2","2","71.54","M","WT","0","1","0","0","Tum Patient 155","5-FU + RT","71.54","rectal tumor"
"GSM2325393","Patient 156 tumor sample","GSM2325393","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 156","age: 69.9","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 67.76","death due to tumor: 0","survival time (month): 67.76","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325393/suppl/GSM2325393_US22502691_252665211079_S01_GE1_107_Sep09_1_3.txt.gz","34127","69.9","0","0","1","3","67.76","M","WT","1","0","0","0","Tum Patient 156","5-FU + Oxaliplatin + RT","67.76","rectal tumor"
"GSM2325394","Patient 157 tumor sample","GSM2325394","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 157","age: 63.6","gender: F","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 72.03","death due to tumor: 0","survival time (month): 72.03","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325394/suppl/GSM2325394_US22502691_252665211166_S01_GE1_107_Sep09_1_1.txt.gz","34127","63.6","0","0","3","3","72.03","F","G13D","0","1","0","0","Tum Patient 157","5-FU + Oxaliplatin + RT","72.03","rectal tumor"
"GSM2325395","Patient 158 tumor sample","GSM2325395","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 158","age: 59","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 8.45","death due to tumor: 1","survival time (month): 27.12","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325395/suppl/GSM2325395_US22502691_252665211071_S01_GE1_107_Sep09_1_3.txt.gz","34127","59","1","1","3","3","8.45","F","WT","0","1","0","0","Tum Patient 158","5-FU + RT","27.12","rectal tumor"
"GSM2325396","Patient 159 tumor sample","GSM2325396","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 159","age: 53.1","gender: F","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 59.8","death due to tumor: 0","survival time (month): 59.8","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325396/suppl/GSM2325396_US22502691_252665211097_S01_GE1_107_Sep09_1_1.txt.gz","34127","53.1","0","0","0","3","59.8","F","G12D","0","0","0","0","Tum Patient 159","5-FU + Oxaliplatin + RT","59.8","rectal tumor"
"GSM2325397","Patient 160 tumor sample","GSM2325397","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 160","age: 65.3","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 37.02","death due to tumor: 0","survival time (month): 37.02","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325397/suppl/GSM2325397_US22502691_252665211078_S01_GE1_107_Sep09_1_1.txt.gz","34127","65.3","0","0","3","4","37.02","M","WT","2","0","0","0","Tum Patient 160","5-FU + RT","37.02","rectal tumor"
"GSM2325398","Patient 161 tumor sample","GSM2325398","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 161","age: 70.6","gender: M","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 29.36","death due to tumor: 0","survival time (month): 29.36","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325398/suppl/GSM2325398_US22502691_252665211155_S01_GE1_107_Sep09_1_1.txt.gz","34127","70.6","0","0","3","3","29.36","M","G12D","0","0","0","0","Tum Patient 161","5-FU + Oxaliplatin + RT","29.36","rectal tumor"
"GSM2325399","Patient 162 tumor sample","GSM2325399","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 162","age: 46.2","gender: M","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 50.14","death due to tumor: 0","survival time (month): 50.14","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325399/suppl/GSM2325399_US22502691_252665211203_S01_GE1_107_Sep09_1_2.txt.gz","34127","46.2","0","0","2","3","50.14","M","G12D","0","0","0","0","Tum Patient 162","5-FU + Oxaliplatin + RT","50.14","rectal tumor"
"GSM2325400","Patient 163 tumor sample","GSM2325400","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 163","age: 63.9","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 16.73","death due to tumor: 0","survival time (month): 16.73","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325400/suppl/GSM2325400_US22502691_252665211192_S01_GE1_107_Sep09_1_4.txt.gz","34127","63.9","0","0","4","4","16.73","M","WT","1","1","0","0","Tum Patient 163","5-FU + Oxaliplatin + RT","16.73","rectal tumor"
"GSM2325401","Patient 164 tumor sample","GSM2325401","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 164","age: 47.5","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 7.1","death due to tumor: 0","survival time (month): 7.1","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325401/suppl/GSM2325401_US22502691_252665211155_S01_GE1_107_Sep09_1_2.txt.gz","34127","47.5","0","0","3","3","7.1","M","WT","1","1","0","0","Tum Patient 164","5-FU + Oxaliplatin + RT","7.1","rectal tumor"
"GSM2325402","Patient 165 tumor sample","GSM2325402","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 165","age: 77.7","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 7.73","death due to tumor: 0","survival time (month): 7.73","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325402/suppl/GSM2325402_US22502691_252665211075_S01_GE1_107_Sep09_1_3.txt.gz","34127","77.7","0","0","0","3","7.73","M","WT","0","0","0","0","Tum Patient 165","5-FU + RT","7.73","rectal tumor"
"GSM2325403","Patient 166 tumor sample","GSM2325403","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 166","age: 56.5","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 0","death due to tumor: 0","survival time (month): 0","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325403/suppl/GSM2325403_US22502691_252665211072_S01_GE1_107_Sep09_1_1.txt.gz","34127","56.5","0","0","2","3","0","F","WT","0","0","0","0","Tum Patient 166","5-FU + Oxaliplatin + RT","0","rectal tumor"
"GSM2325404","Patient 167 tumor sample","GSM2325404","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 167","age: 52.4","gender: M","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 11.9","death due to tumor: 0","survival time (month): 11.9","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325404/suppl/GSM2325404_US22502691_252665211172_S01_GE1_107_Sep09_1_1.txt.gz","34127","52.4","0","0","1","3","11.9","M","G13D","0","1","0","0","Tum Patient 167","5-FU + Oxaliplatin + RT","11.9","rectal tumor"
"GSM2325405","Patient 168 tumor sample","GSM2325405","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 168","age: 59.1","gender: M","tissue: rectal tumor","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 0","death due to tumor: 0","survival time (month): 0","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325405/suppl/GSM2325405_US22502691_252665211069_S01_GE1_107_Sep09_1_3.txt.gz","34127","59.1","0","0","1","3","0","M","NA","0","1","0","0","Tum Patient 168","5-FU + RT","0","rectal tumor"
"GSM2325406","Patient 169 tumor sample","GSM2325406","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 169","age: 69","gender: M","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 5.85","death due to tumor: 0","survival time (month): 5.85","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325406/suppl/GSM2325406_US22502691_252665211074_S01_GE1_107_Sep09_1_1.txt.gz","34127","69","0","0","3","3","5.85","M","G13D","0","1","0","0","Tum Patient 169","5-FU + RT","5.85","rectal tumor"
"GSM2325407","Patient 170 tumor sample","GSM2325407","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 170","age: 64.3","gender: M","tissue: rectal tumor","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: NA","disease free time (month): NA","death due to tumor: NA","survival time (month): NA","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325407/suppl/GSM2325407_US22502691_252665211101_S01_GE1_107_Sep09_1_3.txt.gz","34127","64.3","NA","NA","4","4","NA","M","NA","0","1","0","0","Tum Patient 170","5-FU + RT","NA","rectal tumor"
"GSM2325408","Patient 171 tumor sample","GSM2325408","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 171","age: 65.7","gender: M","tissue: rectal tumor","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: NA","disease free time (month): NA","death due to tumor: NA","survival time (month): NA","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325408/suppl/GSM2325408_US22502691_252665211076_S01_GE1_107_Sep09_1_1.txt.gz","34127","65.7","NA","NA","2","3","NA","M","NA","0","1","0","0","Tum Patient 171","5-FU + RT","NA","rectal tumor"
"GSM2325409","Patient 172 tumor sample","GSM2325409","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 172","age: 65.2","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 5.39","death due to tumor: 0","survival time (month): 5.39","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325409/suppl/GSM2325409_US22502691_252665211223_S01_GE1_107_Sep09_1_3.txt.gz","34127","65.2","0","0","0","3","5.39","M","WT","0","0","0","0","Tum Patient 172","5-FU + RT","5.39","rectal tumor"
"GSM2325410","Patient 173 tumor sample","GSM2325410","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 173","age: 47.6","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 0","death due to tumor: 0","survival time (month): 0","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325410/suppl/GSM2325410_US22502691_252665211224_S01_GE1_107_Sep09_1_2.txt.gz","34127","47.6","0","0","4","4","0","M","WT","2","1","0","0","Tum Patient 173","5-FU + Oxaliplatin + RT","0","rectal tumor"
"GSM2325411","Patient 174 tumor sample","GSM2325411","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 174","age: 60.3","gender: M","tissue: rectal tumor","kras mutation: G12C","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 110.96","death due to tumor: 0","survival time (month): 110.96","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325411/suppl/GSM2325411_US22502691_252665211073_S01_GE1_107_Sep09_1_2.txt.gz","34127","60.3","0","0","0","3","110.96","M","G12C","0","0","0","0","Tum Patient 174","5-FU + Oxaliplatin + RT","110.96","rectal tumor"
"GSM2325412","Patient 175 tumor sample","GSM2325412","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 175","age: 70.9","gender: F","tissue: rectal tumor","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 152.48","death due to tumor: 0","survival time (month): 152.48","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325412/suppl/GSM2325412_US22502691_252665211138_S01_GE1_107_Sep09_1_3.txt.gz","34127","70.9","0","0","1","3","152.48","F","G12V","0","1","0","0","Tum Patient 175","5-FU + RT","152.48","rectal tumor"
"GSM2325413","Patient 176 tumor sample","GSM2325413","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 176","age: 56.3","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 126.74","death due to tumor: 0","survival time (month): 126.74","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325413/suppl/GSM2325413_US22502691_252665211172_S01_GE1_107_Sep09_1_2.txt.gz","34127","56.3","0","0","2","3","126.74","M","WT","0","1","0","0","Tum Patient 176","5-FU + RT","126.74","rectal tumor"
"GSM2325414","Patient 177 tumor sample","GSM2325414","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 177","age: 53.7","gender: M","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 143.41","death due to tumor: 0","survival time (month): 143.41","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325414/suppl/GSM2325414_US22502691_252665211162_S01_GE1_107_Sep09_1_3.txt.gz","34127","53.7","0","0","3","3","143.41","M","G12D","0","1","0","0","Tum Patient 177","5-FU + RT","143.41","rectal tumor"
"GSM2325415","Patient 178 tumor sample","GSM2325415","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 178","age: 55.8","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 96.66","death due to tumor: 0","survival time (month): 96.66","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325415/suppl/GSM2325415_US22502691_252665211073_S01_GE1_107_Sep09_1_1.txt.gz","34127","55.8","0","0","3","3","96.66","M","WT","0","1","0","0","Tum Patient 178","5-FU + RT","96.66","rectal tumor"
"GSM2325416","Patient 179 tumor sample","GSM2325416","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 179","age: 61.6","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 33.47","death due to tumor: 1","survival time (month): 57.93","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325416/suppl/GSM2325416_US22502691_252665211215_S01_GE1_107_Sep09_1_1.txt.gz","34127","61.6","1","1","4","3","33.47","F","WT","1","1","0","0","Tum Patient 179","5-FU + RT","57.93","rectal tumor"
"GSM2325417","Patient 180 tumor sample","GSM2325417","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 180","age: 59.3","gender: M","tissue: rectal tumor","kras mutation: G12W","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 5.52","death due to tumor: 1","survival time (month): 21.44","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325417/suppl/GSM2325417_US22502691_252665211097_S01_GE1_107_Sep09_1_3.txt.gz","34127","59.3","1","1","3","3","5.52","M","G12W","0","0","0","0","Tum Patient 180","5-FU + RT","21.44","rectal tumor"
"GSM2325418","Patient 181 tumor sample","GSM2325418","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 181","age: 62.5","gender: M","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 11.64","death due to tumor: 1","survival time (month): 85.64","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325418/suppl/GSM2325418_US22502691_252665211203_S01_GE1_107_Sep09_1_1.txt.gz","34127","62.5","1","1","3","3","11.64","M","G12D","0","0","0","0","Tum Patient 181","5-FU + RT","85.64","rectal tumor"
"GSM2325419","Patient 182 tumor sample","GSM2325419","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 182","age: 68.5","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 103.1","death due to tumor: 0","survival time (month): 103.1","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325419/suppl/GSM2325419_US22502691_252665211068_S01_GE1_107_Sep09_1_1.txt.gz","34127","68.5","0","0","2","3","103.1","M","WT","0","0","0","0","Tum Patient 182","5-FU + RT","103.1","rectal tumor"
"GSM2325420","Patient 183 tumor sample","GSM2325420","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 183","age: 62.6","gender: M","tissue: rectal tumor","kras mutation: G12C","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 12.33","death due to tumor: 0","survival time (month): 143.54","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325420/suppl/GSM2325420_US22502691_252665211068_S01_GE1_107_Sep09_1_2.txt.gz","34127","62.6","1","0","3","3","12.33","M","G12C","0","1","0","0","Tum Patient 183","5-FU + RT","143.54","rectal tumor"
"GSM2325421","Patient 184 tumor sample","GSM2325421","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 184","age: 60.3","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 40.01","death due to tumor: 1","survival time (month): 73.94","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325421/suppl/GSM2325421_US22502691_252665211073_S01_GE1_107_Sep09_1_3.txt.gz","34127","60.3","1","1","1","3","40.01","M","WT","1","0","0","0","Tum Patient 184","5-FU + RT","73.94","rectal tumor"
"GSM2325422","Patient 185 tumor sample","GSM2325422","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 185","age: 72","gender: M","tissue: rectal tumor","kras mutation: G12S","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 120.26","death due to tumor: 0","survival time (month): 120.26","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325422/suppl/GSM2325422_US22502691_252665211215_S01_GE1_107_Sep09_1_2.txt.gz","34127","72","0","0","2","3","120.26","M","G12S","0","0","0","0","Tum Patient 185","5-FU + RT","120.26","rectal tumor"
"GSM2325423","Patient 186 tumor sample","GSM2325423","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 186","age: 70.9","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 89.92","death due to tumor: 0","survival time (month): 89.92","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325423/suppl/GSM2325423_US22502691_252665211160_S01_GE1_107_Sep09_1_3.txt.gz","34127","70.9","0","0","3","4","89.92","M","WT","2","1","0","0","Tum Patient 186","5-FU + Oxaliplatin + RT","89.92","rectal tumor"
"GSM2325424","Patient 187 tumor sample","GSM2325424","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 187","age: 67.5","gender: F","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 84.13","death due to tumor: 0","survival time (month): 84.13","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325424/suppl/GSM2325424_US22502691_252665211076_S01_GE1_107_Sep09_1_4.txt.gz","34127","67.5","0","0","3","3","84.13","F","G13D","1","0","0","0","Tum Patient 187","5-FU + Oxaliplatin + RT","84.13","rectal tumor"
"GSM2325425","Patient 188 tumor sample","GSM2325425","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 188","age: 70.5","gender: M","tissue: rectal tumor","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 10.75","death due to tumor: 1","survival time (month): 40.24","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325425/suppl/GSM2325425_US22502691_252665211208_S01_GE1_107_Sep09_1_1.txt.gz","34127","70.5","1","1","3","3","10.75","M","G12V","1","1","0","0","Tum Patient 188","5-FU + Oxaliplatin + RT","40.24","rectal tumor"
"GSM2325426","Patient 189 tumor sample","GSM2325426","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 189","age: 61.5","gender: M","tissue: rectal tumor","kras mutation: Q61R","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 115.1","death due to tumor: 0","survival time (month): 115.1","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325426/suppl/GSM2325426_US22502691_252665211101_S01_GE1_107_Sep09_1_4.txt.gz","34127","61.5","0","0","1","3","115.1","M","Q61R","0","0","0","0","Tum Patient 189","5-FU + RT","115.1","rectal tumor"
"GSM2325427","Patient 190 tumor sample","GSM2325427","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 190","age: 53.8","gender: M","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 1","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 0","death due to tumor: 1","survival time (month): 77.23","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325427/suppl/GSM2325427_US22502691_252665211226_S01_GE1_107_Sep09_1_1.txt.gz","34127","53.8","1","1","2","3","0","M","G12D","1","0","1","0","Tum Patient 190","5-FU + RT","77.23","rectal tumor"
"GSM2325428","Patient 191 tumor sample","GSM2325428","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 191","age: 36.2","gender: F","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 8.32","death due to tumor: 1","survival time (month): 14.37","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325428/suppl/GSM2325428_US22502691_252665211170_S01_GE1_107_Sep09_1_3.txt.gz","34127","36.2","1","1","1","3","8.32","F","G13D","0","1","0","0","Tum Patient 191","5-FU + Oxaliplatin + RT","14.37","rectal tumor"
"GSM2325429","Patient 192 tumor sample","GSM2325429","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 192","age: 58.6","gender: M","tissue: rectal tumor","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 86.5","death due to tumor: 0","survival time (month): 86.5","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325429/suppl/GSM2325429_US22502691_252665211170_S01_GE1_107_Sep09_1_4.txt.gz","34127","58.6","0","0","4","4","86.5","M","G12D","2","1","0","0","Tum Patient 192","5-FU + RT","86.5","rectal tumor"
"GSM2325430","Patient 193 tumor sample","GSM2325430","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 193","age: 53.8","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 97.28","death due to tumor: 0","survival time (month): 97.28","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325430/suppl/GSM2325430_US22502691_252665211073_S01_GE1_107_Sep09_1_4.txt.gz","34127","53.8","0","0","0","3","97.28","M","WT","0","0","0","0","Tum Patient 193","5-FU + RT","97.28","rectal tumor"
"GSM2325431","Patient 194 tumor sample","GSM2325431","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 194","age: 61.3","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 73.22","death due to tumor: 0","survival time (month): 73.22","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325431/suppl/GSM2325431_US22502691_252665211192_S01_GE1_107_Sep09_1_3.txt.gz","34127","61.3","0","0","3","3","73.22","M","WT","1","1","0","0","Tum Patient 194","5-FU + RT","73.22","rectal tumor"
"GSM2325432","Patient 195 tumor sample","GSM2325432","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 195","age: 54.9","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 4.83","death due to tumor: 0","survival time (month): 66.74","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325432/suppl/GSM2325432_US22502691_252665211072_S01_GE1_107_Sep09_1_3.txt.gz","34127","54.9","1","0","3","3","4.83","M","WT","0","1","0","0","Tum Patient 195","5-FU + Oxaliplatin + RT","66.74","rectal tumor"
"GSM2325433","Patient 196 tumor sample","GSM2325433","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 196","age: 63.6","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + Cetuximab + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 69.34","death due to tumor: 0","survival time (month): 69.34","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325433/suppl/GSM2325433_US22502691_252665211226_S01_GE1_107_Sep09_1_2.txt.gz","34127","63.6","0","0","0","3","69.34","M","WT","0","1","0","0","Tum Patient 196","5-FU + Oxaliplatin + Cetuximab + RT","69.34","rectal tumor"
"GSM2325434","Patient 197 tumor sample","GSM2325434","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 197","age: 61.9","gender: M","tissue: rectal tumor","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 2","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 86.1","death due to tumor: 0","survival time (month): 86.1","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325434/suppl/GSM2325434_US22502691_252665211079_S01_GE1_107_Sep09_1_1.txt.gz","34127","61.9","0","0","1","2","86.1","M","G12V","1","1","0","0","Tum Patient 197","5-FU + RT","86.1","rectal tumor"
"GSM2325435","Patient 198 tumor sample","GSM2325435","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 198","age: 41.7","gender: M","tissue: rectal tumor","kras mutation: G12A","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 0","death due to tumor: 0","survival time (month): 61.32","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325435/suppl/GSM2325435_US22502691_252665211089_S01_GE1_107_Sep09_1_1.txt.gz","34127","41.7","1","0","3","3","0","M","G12A","0","1","1","1","Tum Patient 198","5-FU + Oxaliplatin + RT","61.32","rectal tumor"
"GSM2325436","Patient 199 tumor sample","GSM2325436","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 199","age: 68.1","gender: M","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 0","death due to tumor: 0","survival time (month): 40.73","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325436/suppl/GSM2325436_US22502691_252665211228_S01_GE1_107_Sep09_1_1.txt.gz","34127","68.1","1","0","3","3","0","M","G13D","0","0","1","1","Tum Patient 199","5-FU + Oxaliplatin + RT","40.73","rectal tumor"
"GSM2325437","Patient 200 tumor sample","GSM2325437","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 200","age: 67.1","gender: F","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 3.48","death due to tumor: 0","survival time (month): 3.48","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325437/suppl/GSM2325437_US22502691_252665211208_S01_GE1_107_Sep09_1_2.txt.gz","34127","67.1","0","0","3","3","3.48","F","WT","2","1","0","0","Tum Patient 200","5-FU + RT","3.48","rectal tumor"
"GSM2325438","Patient 201 tumor sample","GSM2325438","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 201","age: 72","gender: M","tissue: rectal tumor","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 18.64","death due to tumor: 0","survival time (month): 72.23","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325438/suppl/GSM2325438_US22502691_252665211104_S01_GE1_107_Sep09_1_3.txt.gz","34127","72","1","0","3","3","18.64","M","WT","1","1","0","0","Tum Patient 201","5-FU + RT","72.23","rectal tumor"
"GSM2325439","Patient 202 tumor sample","GSM2325439","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 202","age: 66.8","gender: M","tissue: rectal tumor","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 70.09","death due to tumor: 0","survival time (month): 70.09","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325439/suppl/GSM2325439_US22502691_252665211138_S01_GE1_107_Sep09_1_4.txt.gz","34127","66.8","0","0","3","3","70.09","M","G13D","0","0","0","0","Tum Patient 202","5-FU + RT","70.09","rectal tumor"
"GSM2325440","Patient 203 tumor sample","GSM2325440","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","rectal tumor","Homo sapiens","patient: Tum Patient 203","age: 69.4","gender: F","tissue: rectal tumor","kras mutation: K117N","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 0","death due to tumor: 0","survival time (month): 71.77","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325440/suppl/GSM2325440_US22502691_252665211162_S01_GE1_107_Sep09_1_4.txt.gz","34127","69.4","1","0","3","4","0","F","K117N","0","1","1","1","Tum Patient 203","5-FU + RT","71.77","rectal tumor"
"GSM2325441","Patient 1 mucosa control sample","GSM2325441","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 1","age: 55.6","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -4.08","death due to tumor: 0","survival time (month): 41.92","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325441/suppl/GSM2325441_US22502691_252665211104_S01_GE1_107_Sep09_1_2.txt.gz","34127","55.6","1","0","3","3","-4.08","F","WT","1","1","1","1","Con Patient 1","5-FU + Oxaliplatin + RT","41.92","mucosa"
"GSM2325442","Patient 2 mucosa control sample","GSM2325442","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 2","age: 65.6","gender: M","tissue: mucosa","kras mutation: I21L","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 40.27","death due to tumor: 0","survival time (month): 40.27","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325442/suppl/GSM2325442_US22502691_252665211182_S01_GE1_107_Sep09_1_2.txt.gz","34127","65.6","0","0","0","3","40.27","M","I21L","0","1","0","0","Con Patient 2","5-FU + RT","40.27","mucosa"
"GSM2325443","Patient 3 mucosa control sample","GSM2325443","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 3","age: 62.7","gender: M","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 29.62","death due to tumor: 0","survival time (month): 29.62","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325443/suppl/GSM2325443_US22502691_252665211184_S01_GE1_107_Sep09_1_4.txt.gz","34127","62.7","0","0","0","3","29.62","M","G12D","0","0","0","0","Con Patient 3","5-FU + RT","29.62","mucosa"
"GSM2325444","Patient 4 mucosa control sample","GSM2325444","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 4","age: 61.8","gender: M","tissue: mucosa","kras mutation: G12A","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 32.65","death due to tumor: 0","survival time (month): 32.65","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325444/suppl/GSM2325444_US22502691_252665211155_S01_GE1_107_Sep09_1_4.txt.gz","34127","61.8","0","0","0","3","32.65","M","G12A","0","1","0","0","Con Patient 4","5-FU + Oxaliplatin + RT","32.65","mucosa"
"GSM2325445","Patient 5 mucosa control sample","GSM2325445","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 5","age: 52.1","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 31.59","death due to tumor: 0","survival time (month): 31.59","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325445/suppl/GSM2325445_US22502691_252665211157_S01_GE1_107_Sep09_1_2.txt.gz","34127","52.1","0","0","0","3","31.59","F","WT","0","1","0","0","Con Patient 5","5-FU + RT","31.59","mucosa"
"GSM2325446","Patient 6 mucosa control sample","GSM2325446","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 6","age: 59.1","gender: M","tissue: mucosa","kras mutation: G12C","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 34.52","death due to tumor: 0","survival time (month): 34.52","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325446/suppl/GSM2325446_US22502691_252665211176_S01_GE1_107_Sep09_1_2.txt.gz","34127","59.1","0","0","2","3","34.52","M","G12C","0","0","0","0","Con Patient 6","5-FU + Oxaliplatin + RT","34.52","mucosa"
"GSM2325447","Patient 7 mucosa control sample","GSM2325447","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 7","age: 70.7","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 32.68","death due to tumor: 0","survival time (month): 32.68","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325447/suppl/GSM2325447_US22502691_252665211159_S01_GE1_107_Sep09_1_2.txt.gz","34127","70.7","0","0","0","3","32.68","M","WT","0","0","0","0","Con Patient 7","5-FU + RT","32.68","mucosa"
"GSM2325448","Patient 8 mucosa control sample","GSM2325448","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 8","age: 60.7","gender: M","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 30.31","death due to tumor: 0","survival time (month): 30.31","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325448/suppl/GSM2325448_US22502691_252665211203_S01_GE1_107_Sep09_1_4.txt.gz","34127","60.7","0","0","2","3","30.31","M","G12D","0","1","0","0","Con Patient 8","5-FU + RT","30.31","mucosa"
"GSM2325449","Patient 9 mucosa control sample","GSM2325449","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 9","age: 55","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 28.08","death due to tumor: 0","survival time (month): 28.08","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325449/suppl/GSM2325449_US22502691_252665211065_S01_GE1_107_Sep09_1_4.txt.gz","34127","55","0","0","2","3","28.08","M","WT","0","0","0","0","Con Patient 9","5-FU + Oxaliplatin + RT","28.08","mucosa"
"GSM2325450","Patient 10 mucosa control sample","GSM2325450","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 10","age: 53.1","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 27.55","death due to tumor: 0","survival time (month): 27.55","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325450/suppl/GSM2325450_US22502691_252665211069_S01_GE1_107_Sep09_1_2.txt.gz","34127","53.1","0","0","3","3","27.55","M","WT","1","1","0","0","Con Patient 10","5-FU + RT","27.55","mucosa"
"GSM2325451","Patient 11 mucosa control sample","GSM2325451","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 11","age: NA","gender: M","tissue: mucosa","kras mutation: A146T","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: NA","lymph node metastasis after rct: NA","metastasis after rct: NA","cancer recurrance after surgery: 0","disease free time (month): NA","death due to tumor: 0","survival time (month): NA","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325451/suppl/GSM2325451_US22502691_252665211219_S01_GE1_107_Sep09_1_4.txt.gz","34127","NA","0","0","NA","3","NA","M","A146T","NA","0","NA","0","Con Patient 11","5-FU + Oxaliplatin + RT","NA","mucosa"
"GSM2325452","Patient 12 mucosa control sample","GSM2325452","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 12","age: 58.6","gender: M","tissue: mucosa","kras mutation: G12C","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 14.93","death due to tumor: 0","survival time (month): 14.93","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325452/suppl/GSM2325452_US22502691_252665211214_S01_GE1_107_Sep09_1_4.txt.gz","34127","58.6","0","0","2","3","14.93","M","G12C","1","0","0","0","Con Patient 12","5-FU + RT","14.93","mucosa"
"GSM2325453","Patient 13 mucosa control sample","GSM2325453","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 13","age: 68.5","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 23.38","death due to tumor: 0","survival time (month): 23.38","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325453/suppl/GSM2325453_US22502691_252665211189_S01_GE1_107_Sep09_1_4.txt.gz","34127","68.5","0","0","0","3","23.38","M","WT","0","1","0","0","Con Patient 13","5-FU + RT","23.38","mucosa"
"GSM2325454","Patient 14 mucosa control sample","GSM2325454","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 14","age: 58.8","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 2","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 6.71","death due to tumor: 0","survival time (month): 25.81","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325454/suppl/GSM2325454_US22502691_252665211086_S01_GE1_107_Sep09_1_2.txt.gz","34127","58.8","1","0","3","2","6.71","M","WT","1","1","1","1","Con Patient 14","5-FU + Oxaliplatin + RT","25.81","mucosa"
"GSM2325455","Patient 15 mucosa control sample","GSM2325455","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 15","age: 70.1","gender: M","tissue: mucosa","kras mutation: G12S","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: NA","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 13.02","death due to tumor: 0","survival time (month): 13.02","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325455/suppl/GSM2325455_US22502691_252665211088_S01_GE1_107_Sep09_1_2.txt.gz","34127","70.1","0","0","2","NA","13.02","M","G12S","1","1","0","0","Con Patient 15","5-FU + Oxaliplatin + RT","13.02","mucosa"
"GSM2325456","Patient 16 mucosa control sample","GSM2325456","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 16","age: 77.6","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: NA","metastasis before rct: NA","depth of invasion after rct: 4","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 34.72","death due to tumor: 0","survival time (month): 34.72","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325456/suppl/GSM2325456_US22502691_252665211183_S01_GE1_107_Sep09_1_2.txt.gz","34127","77.6","0","0","4","3","34.72","F","G12D","0","NA","0","NA","Con Patient 16","5-FU + RT","34.72","mucosa"
"GSM2325457","Patient 17 mucosa control sample","GSM2325457","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 17","age: 68.5","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: NA","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -2.63","death due to tumor: 0","survival time (month): 18.28","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325457/suppl/GSM2325457_US22502691_252665211213_S01_GE1_107_Sep09_1_4.txt.gz","34127","68.5","1","0","3","3","-2.63","F","WT","2","NA","1","1","Con Patient 17","5-FU + RT","18.28","mucosa"
"GSM2325458","Patient 18 mucosa control sample","GSM2325458","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 18","age: 75.2","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: NA","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -3.32","death due to tumor: 1","survival time (month): 10.26","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325458/suppl/GSM2325458_US22502691_252665211213_S01_GE1_107_Sep09_1_2.txt.gz","34127","75.2","1","1","3","3","-3.32","M","WT","2","NA","1","1","Con Patient 18","5-FU + RT","10.26","mucosa"
"GSM2325459","Patient 19 mucosa control sample","GSM2325459","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 19","age: 76.3","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: NA","metastasis before rct: NA","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 10.62","death due to tumor: 0","survival time (month): 10.62","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325459/suppl/GSM2325459_US22502691_252665211205_S01_GE1_107_Sep09_1_2.txt.gz","34127","76.3","0","0","3","3","10.62","M","WT","0","NA","0","NA","Con Patient 19","5-FU + RT","10.62","mucosa"
"GSM2325460","Patient 20 mucosa control sample","GSM2325460","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 20","age: 38.2","gender: M","tissue: mucosa","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 8.25","death due to tumor: 0","survival time (month): 8.25","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325460/suppl/GSM2325460_US22502691_252665211098_S01_GE1_107_Sep09_1_2.txt.gz","34127","38.2","0","0","2","3","8.25","M","G13D","0","1","0","0","Con Patient 20","5-FU + RT","8.25","mucosa"
"GSM2325461","Patient 21 mucosa control sample","GSM2325461","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 21","age: 61.1","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -0.62","death due to tumor: 1","survival time (month): 5.75","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325461/suppl/GSM2325461_US22502691_252665211099_S01_GE1_107_Sep09_1_2.txt.gz","34127","61.1","1","1","3","3","-0.62","F","WT","2","0","1","1","Con Patient 21","5-FU + RT","5.75","mucosa"
"GSM2325462","Patient 22 mucosa control sample","GSM2325462","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 22","age: 69.4","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 23.28","death due to tumor: 0","survival time (month): 23.28","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325462/suppl/GSM2325462_US22502691_252665211171_S01_GE1_107_Sep09_1_4.txt.gz","34127","69.4","0","0","3","3","23.28","M","WT","0","0","0","0","Con Patient 22","5-FU + Oxaliplatin + RT","23.28","mucosa"
"GSM2325463","Patient 23 mucosa control sample","GSM2325463","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 23","age: 54.2","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 23.8","death due to tumor: 0","survival time (month): 23.8","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325463/suppl/GSM2325463_US22502691_252665211171_S01_GE1_107_Sep09_1_2.txt.gz","34127","54.2","0","0","2","3","23.8","M","WT","0","0","0","0","Con Patient 23","5-FU + RT","23.8","mucosa"
"GSM2325464","Patient 24 mucosa control sample","GSM2325464","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 24","age: 57.4","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 7.33","death due to tumor: 0","survival time (month): 7.33","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325464/suppl/GSM2325464_US22502691_252665211161_S01_GE1_107_Sep09_1_2.txt.gz","34127","57.4","0","0","1","3","7.33","F","WT","0","0","0","0","Con Patient 24","5-FU + Oxaliplatin + RT","7.33","mucosa"
"GSM2325465","Patient 25 mucosa control sample","GSM2325465","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 25","age: 61.3","gender: M","tissue: mucosa","kras mutation: Q61P","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 15.25","death due to tumor: 0","survival time (month): 24.1","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325465/suppl/GSM2325465_US22502691_252665211204_S01_GE1_107_Sep09_1_2.txt.gz","34127","61.3","1","0","3","3","15.25","M","Q61P","0","1","0","0","Con Patient 25","5-FU + RT","24.1","mucosa"
"GSM2325466","Patient 26 mucosa control sample","GSM2325466","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 26","age: 47","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 22.55","death due to tumor: 0","survival time (month): 22.55","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325466/suppl/GSM2325466_US22502691_252665211066_S01_GE1_107_Sep09_1_2.txt.gz","34127","47","0","0","3","3","22.55","M","WT","0","1","0","0","Con Patient 26","5-FU + Oxaliplatin + RT","22.55","mucosa"
"GSM2325467","Patient 27 mucosa control sample","GSM2325467","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 27","age: 62.7","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 22.22","death due to tumor: 0","survival time (month): 22.22","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325467/suppl/GSM2325467_US22502691_252665211208_S01_GE1_107_Sep09_1_4.txt.gz","34127","62.7","0","0","0","3","22.22","M","WT","0","0","0","0","Con Patient 27","5-FU + RT","22.22","mucosa"
"GSM2325468","Patient 28 mucosa control sample","GSM2325468","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 28","age: 51.3","gender: M","tissue: mucosa","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 17.98","death due to tumor: 0","survival time (month): 17.98","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325468/suppl/GSM2325468_US22502691_252665211222_S01_GE1_107_Sep09_1_4.txt.gz","34127","51.3","0","0","0","3","17.98","M","G13D","0","1","0","0","Con Patient 28","5-FU + RT","17.98","mucosa"
"GSM2325469","Patient 29 mucosa control sample","GSM2325469","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 29","age: 73.3","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 1","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 0","death due to tumor: 0","survival time (month): 6.25","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325469/suppl/GSM2325469_US22502691_252665211207_S01_GE1_107_Sep09_1_2.txt.gz","34127","73.3","1","0","2","3","0","M","WT","1","0","1","0","Con Patient 29","5-FU + RT","6.25","mucosa"
"GSM2325470","Patient 30 mucosa control sample","GSM2325470","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 30","age: 47.2","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -2.99","death due to tumor: 0","survival time (month): 13.12","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325470/suppl/GSM2325470_US22502691_252665211177_S01_GE1_107_Sep09_1_2.txt.gz","34127","47.2","1","0","3","3","-2.99","F","WT","1","1","1","1","Con Patient 30","5-FU + Oxaliplatin + RT","13.12","mucosa"
"GSM2325471","Patient 31 mucosa control sample","GSM2325471","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 31","age: 72.7","gender: F","tissue: mucosa","kras mutation: G12S","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 16.21","death due to tumor: 0","survival time (month): 16.21","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325471/suppl/GSM2325471_US22502691_252665211067_S01_GE1_107_Sep09_1_4.txt.gz","34127","72.7","0","0","3","3","16.21","F","G12S","0","0","0","0","Con Patient 31","5-FU + RT","16.21","mucosa"
"GSM2325472","Patient 32 mucosa control sample","GSM2325472","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 32","age: 38.8","gender: M","tissue: mucosa","kras mutation: G12C","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 6.38","death due to tumor: 0","survival time (month): 6.38","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325472/suppl/GSM2325472_US22502691_252665211158_S01_GE1_107_Sep09_1_2.txt.gz","34127","38.8","0","0","3","4","6.38","M","G12C","2","1","0","0","Con Patient 32","5-FU + Oxaliplatin + RT","6.38","mucosa"
"GSM2325473","Patient 33 mucosa control sample","GSM2325473","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 33","age: 75.5","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 13.02","death due to tumor: 0","survival time (month): 13.02","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325473/suppl/GSM2325473_US22502691_252665211172_S01_GE1_107_Sep09_1_4.txt.gz","34127","75.5","0","0","3","3","13.02","M","WT","0","0","0","0","Con Patient 33","5-FU + RT","13.02","mucosa"
"GSM2325474","Patient 34 mucosa control sample","GSM2325474","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 34","age: 80","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 2.96","death due to tumor: 0","survival time (month): 2.96","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325474/suppl/GSM2325474_US22502691_252665211191_S01_GE1_107_Sep09_1_4.txt.gz","34127","80","0","0","0","3","2.96","F","WT","0","1","0","0","Con Patient 34","5-FU + Oxaliplatin + RT","2.96","mucosa"
"GSM2325475","Patient 35 mucosa control sample","GSM2325475","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 35","age: 60.9","gender: M","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 13.05","death due to tumor: 0","survival time (month): 13.05","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325475/suppl/GSM2325475_US22502691_252665211160_S01_GE1_107_Sep09_1_2.txt.gz","34127","60.9","0","0","3","3","13.05","M","G12D","1","1","0","0","Con Patient 35","5-FU + RT","13.05","mucosa"
"GSM2325476","Patient 36 mucosa control sample","GSM2325476","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 36","age: 76.3","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 1.74","death due to tumor: 0","survival time (month): 1.74","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325476/suppl/GSM2325476_US22502691_252665211181_S01_GE1_107_Sep09_1_4.txt.gz","34127","76.3","0","0","3","3","1.74","M","WT","0","1","0","0","Con Patient 36","5-FU + RT","1.74","mucosa"
"GSM2325477","Patient 37 mucosa control sample","GSM2325477","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 37","age: 49.5","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 12.59","death due to tumor: 0","survival time (month): 12.59","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325477/suppl/GSM2325477_US22502691_252665211141_S01_GE1_107_Sep09_1_2.txt.gz","34127","49.5","0","0","1","3","12.59","F","WT","0","0","0","0","Con Patient 37","5-FU + Oxaliplatin + RT","12.59","mucosa"
"GSM2325478","Patient 38 mucosa control sample","GSM2325478","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 38","age: 49.9","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 11.57","death due to tumor: 0","survival time (month): 11.57","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325478/suppl/GSM2325478_US22502691_252665211224_S01_GE1_107_Sep09_1_4.txt.gz","34127","49.9","0","0","0","3","11.57","M","WT","0","0","0","0","Con Patient 38","5-FU + Oxaliplatin + RT","11.57","mucosa"
"GSM2325479","Patient 39 mucosa control sample","GSM2325479","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 39","age: 57.6","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 9.83","death due to tumor: 0","survival time (month): 9.83","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325479/suppl/GSM2325479_US22502691_252665211220_S01_GE1_107_Sep09_1_2.txt.gz","34127","57.6","0","0","2","3","9.83","M","WT","0","1","0","0","Con Patient 39","5-FU + RT","9.83","mucosa"
"GSM2325480","Patient 40 mucosa control sample","GSM2325480","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 40","age: 77.3","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 8.28","death due to tumor: 0","survival time (month): 8.28","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325480/suppl/GSM2325480_US22502691_252665211258_S01_GE1_107_Sep09_1_2.txt.gz","34127","77.3","0","0","2","3","8.28","M","WT","1","1","0","0","Con Patient 40","5-FU + Oxaliplatin + RT","8.28","mucosa"
"GSM2325481","Patient 41 mucosa control sample","GSM2325481","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 41","age: 72.4","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 22.68","death due to tumor: 0","survival time (month): 22.68","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325481/suppl/GSM2325481_US22502691_252665211190_S01_GE1_107_Sep09_1_4.txt.gz","34127","72.4","1","0","3","3","22.68","M","WT","1","1","0","0","Con Patient 41","5-FU + RT","22.68","mucosa"
"GSM2325482","Patient 42 mucosa control sample","GSM2325482","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 42","age: 76.3","gender: M","tissue: mucosa","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 20.19","death due to tumor: 0","survival time (month): 20.19","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325482/suppl/GSM2325482_US22502691_252665211175_S01_GE1_107_Sep09_1_4.txt.gz","34127","76.3","0","0","2","3","20.19","M","G13D","0","1","0","0","Con Patient 42","5-FU + RT","20.19","mucosa"
"GSM2325483","Patient 43 mucosa control sample","GSM2325483","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 43","age: 61.4","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 0","death due to tumor: 0","survival time (month): 0","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325483/suppl/GSM2325483_US22502691_252665211212_S01_GE1_107_Sep09_1_2.txt.gz","34127","61.4","0","0","3","3","0","M","WT","1","1","0","0","Con Patient 43","5-FU + Oxaliplatin + RT","0","mucosa"
"GSM2325484","Patient 44 mucosa control sample","GSM2325484","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 44","age: 66.3","gender: F","tissue: mucosa","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 0","death due to tumor: 0","survival time (month): 0","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325484/suppl/GSM2325484_US22502691_252665211225_S01_GE1_107_Sep09_1_4.txt.gz","34127","66.3","0","0","3","3","0","F","NA","1","1","0","0","Con Patient 44","5-FU + Oxaliplatin + RT","0","mucosa"
"GSM2325485","Patient 45 mucosa control sample","GSM2325485","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 45","age: 65.6","gender: M","tissue: mucosa","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 0","death due to tumor: 0","survival time (month): 0","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325485/suppl/GSM2325485_US22502691_252665211065_S01_GE1_107_Sep09_1_2.txt.gz","34127","65.6","0","0","0","3","0","M","NA","0","0","0","0","Con Patient 45","5-FU + RT","0","mucosa"
"GSM2325486","Patient 46 mucosa control sample","GSM2325486","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 46","age: 68.4","gender: M","tissue: mucosa","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: NA","disease free time (month): NA","death due to tumor: NA","survival time (month): NA","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325486/suppl/GSM2325486_US22502691_252665211103_S01_GE1_107_Sep09_1_4.txt.gz","34127","68.4","NA","NA","3","3","NA","M","NA","1","1","0","0","Con Patient 46","5-FU + RT","NA","mucosa"
"GSM2325487","Patient 47 mucosa control sample","GSM2325487","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 47","age: 78.9","gender: M","tissue: mucosa","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 2","lymph node metastasis before rct: 0","metastasis before rct: NA","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: NA","disease free time (month): NA","death due to tumor: NA","survival time (month): NA","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325487/suppl/GSM2325487_US22502691_252665211227_S01_GE1_107_Sep09_1_2.txt.gz","34127","78.9","NA","NA","0","2","NA","M","NA","0","0","0","NA","Con Patient 47","5-FU + RT","NA","mucosa"
"GSM2325488","Patient 48 mucosa control sample","GSM2325488","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 48","age: 65.8","gender: M","tissue: mucosa","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: NA","disease free time (month): NA","death due to tumor: NA","survival time (month): NA","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325488/suppl/GSM2325488_US22502691_252665211207_S01_GE1_107_Sep09_1_4.txt.gz","34127","65.8","NA","NA","2","3","NA","M","NA","0","0","0","0","Con Patient 48","5-FU + RT","NA","mucosa"
"GSM2325489","Patient 49 mucosa control sample","GSM2325489","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 49","age: 57.1","gender: F","tissue: mucosa","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: NA","disease free time (month): NA","death due to tumor: NA","survival time (month): NA","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325489/suppl/GSM2325489_US22502691_252665211066_S01_GE1_107_Sep09_1_4.txt.gz","34127","57.1","NA","NA","0","3","NA","F","NA","0","1","0","0","Con Patient 49","5-FU + RT","NA","mucosa"
"GSM2325490","Patient 50 mucosa control sample","GSM2325490","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 50","age: 74.1","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 29.03","death due to tumor: 0","survival time (month): 29.03","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325490/suppl/GSM2325490_US22502691_252665211174_S01_GE1_107_Sep09_1_2.txt.gz","34127","74.1","1","0","1","3","29.03","M","WT","0","0","0","0","Con Patient 50","5-FU + RT","29.03","mucosa"
"GSM2325491","Patient 51 mucosa control sample","GSM2325491","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 51","age: 48.2","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 1.78","death due to tumor: 0","survival time (month): 1.78","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325491/suppl/GSM2325491_US22502691_252665211204_S01_GE1_107_Sep09_1_4.txt.gz","34127","48.2","0","0","3","4","1.78","M","WT","2","1","0","0","Con Patient 51","5-FU + Oxaliplatin + RT","1.78","mucosa"
"GSM2325492","Patient 52 mucosa control sample","GSM2325492","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 52","age: 56.3","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 0.69","death due to tumor: 0","survival time (month): 0.69","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325492/suppl/GSM2325492_US22502691_252665211223_S01_GE1_107_Sep09_1_2.txt.gz","34127","56.3","0","0","2","3","0.69","F","G12D","0","0","0","0","Con Patient 52","5-FU + RT","0.69","mucosa"
"GSM2325493","Patient 53 mucosa control sample","GSM2325493","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 53","age: 61.9","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 151.17","death due to tumor: 0","survival time (month): 151.17","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325493/suppl/GSM2325493_US22502691_252665211223_S01_GE1_107_Sep09_1_4.txt.gz","34127","61.9","0","0","0","3","151.17","M","WT","0","0","0","0","Con Patient 53","5-FU + RT","151.17","mucosa"
"GSM2325494","Patient 54 mucosa control sample","GSM2325494","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 54","age: 65.4","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 91","death due to tumor: 0","survival time (month): 91","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325494/suppl/GSM2325494_US22502691_252665211173_S01_GE1_107_Sep09_1_4.txt.gz","34127","65.4","0","0","2","3","91","M","WT","0","1","0","0","Con Patient 54","5-FU + RT","91","mucosa"
"GSM2325495","Patient 55 mucosa control sample","GSM2325495","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 55","age: 49.2","gender: M","tissue: mucosa","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 144.3","death due to tumor: 0","survival time (month): 144.3","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325495/suppl/GSM2325495_US22502691_252665211082_S01_GE1_107_Sep09_1_4.txt.gz","34127","49.2","0","0","1","3","144.3","M","G13D","0","0","0","0","Con Patient 55","5-FU + RT","144.3","mucosa"
"GSM2325496","Patient 56 mucosa control sample","GSM2325496","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 56","age: 63.7","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 112.01","death due to tumor: 0","survival time (month): 112.01","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325496/suppl/GSM2325496_US22502691_252665211100_S01_GE1_107_Sep09_1_4.txt.gz","34127","63.7","0","0","1","3","112.01","M","WT","0","1","0","0","Con Patient 56","5-FU + Oxaliplatin + RT","112.01","mucosa"
"GSM2325497","Patient 57 mucosa control sample","GSM2325497","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 57","age: 58.6","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 111.25","death due to tumor: 0","survival time (month): 111.25","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325497/suppl/GSM2325497_US22502691_252665211258_S01_GE1_107_Sep09_1_4.txt.gz","34127","58.6","0","0","3","3","111.25","F","G12D","0","0","0","0","Con Patient 57","5-FU + Oxaliplatin + RT","111.25","mucosa"
"GSM2325498","Patient 58 mucosa control sample","GSM2325498","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 58","age: 66.4","gender: M","tissue: mucosa","kras mutation: Q61L","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 100.04","death due to tumor: 0","survival time (month): 100.04","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325498/suppl/GSM2325498_US22502691_252665211088_S01_GE1_107_Sep09_1_4.txt.gz","34127","66.4","0","0","0","3","100.04","M","Q61L","0","1","0","0","Con Patient 58","5-FU + RT","100.04","mucosa"
"GSM2325499","Patient 59 mucosa control sample","GSM2325499","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 59","age: 62.1","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 3.16","death due to tumor: 0","survival time (month): 3.16","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325499/suppl/GSM2325499_US22502691_252665211183_S01_GE1_107_Sep09_1_4.txt.gz","34127","62.1","0","0","4","3","3.16","M","WT","2","1","0","0","Con Patient 59","5-FU + Oxaliplatin + RT","3.16","mucosa"
"GSM2325500","Patient 60 mucosa control sample","GSM2325500","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 60","age: 57.4","gender: M","tissue: mucosa","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 29.13","death due to tumor: 1","survival time (month): 70.72","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325500/suppl/GSM2325500_US22502691_252665211165_S01_GE1_107_Sep09_1_4.txt.gz","34127","57.4","1","1","2","3","29.13","M","G13D","0","0","0","0","Con Patient 60","5-FU + Oxaliplatin + RT","70.72","mucosa"
"GSM2325501","Patient 61 mucosa control sample","GSM2325501","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 61","age: 48.4","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 112.24","death due to tumor: 0","survival time (month): 112.24","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325501/suppl/GSM2325501_US22502691_252665211186_S01_GE1_107_Sep09_1_2.txt.gz","34127","48.4","0","0","1","3","112.24","F","WT","0","1","0","0","Con Patient 61","5-FU + Oxaliplatin + RT","112.24","mucosa"
"GSM2325502","Patient 62 mucosa control sample","GSM2325502","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 62","age: 71.2","gender: M","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 79.53","death due to tumor: 0","survival time (month): 79.53","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325502/suppl/GSM2325502_US22502691_252665211087_S01_GE1_107_Sep09_1_2.txt.gz","34127","71.2","0","0","2","3","79.53","M","G12D","0","0","0","0","Con Patient 62","5-FU + Oxaliplatin + RT","79.53","mucosa"
"GSM2325503","Patient 63 mucosa control sample","GSM2325503","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 63","age: 71.2","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 109.84","death due to tumor: 0","survival time (month): 109.84","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325503/suppl/GSM2325503_US22502691_252665211188_S01_GE1_107_Sep09_1_2.txt.gz","34127","71.2","0","0","2","3","109.84","F","WT","0","0","0","0","Con Patient 63","5-FU + Oxaliplatin + RT","109.84","mucosa"
"GSM2325504","Patient 64 mucosa control sample","GSM2325504","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 64","age: 52.7","gender: M","tissue: mucosa","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 62.93","death due to tumor: 1","survival time (month): 110.17","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325504/suppl/GSM2325504_US22502691_252665211193_S01_GE1_107_Sep09_1_4.txt.gz","34127","52.7","1","1","2","3","62.93","M","G12V","0","1","0","0","Con Patient 64","5-FU + Oxaliplatin + RT","110.17","mucosa"
"GSM2325505","Patient 65 mucosa control sample","GSM2325505","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 65","age: 70.3","gender: M","tissue: mucosa","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 45.73","death due to tumor: 0","survival time (month): 45.73","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325505/suppl/GSM2325505_US22502691_252665211191_S01_GE1_107_Sep09_1_2.txt.gz","34127","70.3","0","0","3","3","45.73","M","G12V","1","1","0","0","Con Patient 65","5-FU + RT","45.73","mucosa"
"GSM2325506","Patient 66 mucosa control sample","GSM2325506","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 66","age: 54","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 114.35","death due to tumor: 0","survival time (month): 114.35","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325506/suppl/GSM2325506_US22502691_252665211167_S01_GE1_107_Sep09_1_2.txt.gz","34127","54","0","0","1","3","114.35","F","G12D","0","1","0","0","Con Patient 66","5-FU + Oxaliplatin + RT","114.35","mucosa"
"GSM2325507","Patient 67 mucosa control sample","GSM2325507","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 67","age: 53.7","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 58.92","death due to tumor: 1","survival time (month): 84.36","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325507/suppl/GSM2325507_US22502691_252665211175_S01_GE1_107_Sep09_1_2.txt.gz","34127","53.7","1","1","3","3","58.92","M","WT","0","0","0","0","Con Patient 67","5-FU + RT","84.36","mucosa"
"GSM2325508","Patient 68 mucosa control sample","GSM2325508","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 68","age: 60","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 86.79","death due to tumor: 0","survival time (month): 86.79","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325508/suppl/GSM2325508_US22502691_252665211164_S01_GE1_107_Sep09_1_4.txt.gz","34127","60","0","0","3","3","86.79","M","WT","1","1","0","0","Con Patient 68","5-FU + RT","86.79","mucosa"
"GSM2325509","Patient 69 mucosa control sample","GSM2325509","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 69","age: 68.2","gender: M","tissue: mucosa","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 93.96","death due to tumor: 0","survival time (month): 93.96","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325509/suppl/GSM2325509_US22502691_252665211105_S01_GE1_107_Sep09_1_2.txt.gz","34127","68.2","0","0","3","3","93.96","M","G12V","1","0","0","0","Con Patient 69","5-FU + Oxaliplatin + RT","93.96","mucosa"
"GSM2325510","Patient 70 mucosa control sample","GSM2325510","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 70","age: 65.7","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 25.38","death due to tumor: 1","survival time (month): 51.52","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325510/suppl/GSM2325510_US22502691_252665211070_S01_GE1_107_Sep09_1_4.txt.gz","34127","65.7","1","1","3","3","25.38","M","WT","1","1","0","0","Con Patient 70","5-FU + Oxaliplatin + RT","51.52","mucosa"
"GSM2325511","Patient 71 mucosa control sample","GSM2325511","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 71","age: 79.7","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 88.27","death due to tumor: 0","survival time (month): 88.27","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325511/suppl/GSM2325511_US22502691_252665211178_S01_GE1_107_Sep09_1_4.txt.gz","34127","79.7","0","0","2","3","88.27","M","WT","0","1","0","0","Con Patient 71","5-FU + Oxaliplatin + RT","88.27","mucosa"
"GSM2325512","Patient 72 mucosa control sample","GSM2325512","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 72","age: 81.4","gender: F","tissue: mucosa","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 82.98","death due to tumor: 0","survival time (month): 82.98","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325512/suppl/GSM2325512_US22502691_252665211180_S01_GE1_107_Sep09_1_2.txt.gz","34127","81.4","0","0","2","3","82.98","F","G13D","0","1","0","0","Con Patient 72","5-FU + RT","82.98","mucosa"
"GSM2325513","Patient 73 mucosa control sample","GSM2325513","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 73","age: 66.3","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 71.31","death due to tumor: 0","survival time (month): 71.31","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325513/suppl/GSM2325513_US22502691_252665211077_S01_GE1_107_Sep09_1_2.txt.gz","34127","66.3","0","0","1","3","71.31","M","WT","0","1","0","0","Con Patient 73","5-FU + Oxaliplatin + RT","71.31","mucosa"
"GSM2325514","Patient 74 mucosa control sample","GSM2325514","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 74","age: 59.3","gender: M","tissue: mucosa","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 61.25","death due to tumor: 0","survival time (month): 61.25","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325514/suppl/GSM2325514_US22502691_252665211186_S01_GE1_107_Sep09_1_4.txt.gz","34127","59.3","0","0","2","3","61.25","M","G13D","0","1","0","0","Con Patient 74","5-FU + RT","61.25","mucosa"
"GSM2325515","Patient 75 mucosa control sample","GSM2325515","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 75","age: 57.4","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 83.97","death due to tumor: 0","survival time (month): 83.97","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325515/suppl/GSM2325515_US22502691_252665211169_S01_GE1_107_Sep09_1_2.txt.gz","34127","57.4","0","0","2","3","83.97","M","WT","0","1","0","0","Con Patient 75","5-FU + Oxaliplatin + RT","83.97","mucosa"
"GSM2325516","Patient 76 mucosa control sample","GSM2325516","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 76","age: 81.5","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 39.25","death due to tumor: 0","survival time (month): 39.25","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325516/suppl/GSM2325516_US22502691_252665211179_S01_GE1_107_Sep09_1_4.txt.gz","34127","81.5","0","0","3","3","39.25","M","WT","0","0","0","0","Con Patient 76","5-FU + RT","39.25","mucosa"
"GSM2325517","Patient 77 mucosa control sample","GSM2325517","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 77","age: 62.3","gender: M","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 34.39","death due to tumor: 0","survival time (month): 34.39","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325517/suppl/GSM2325517_US22502691_252665211103_S01_GE1_107_Sep09_1_2.txt.gz","34127","62.3","0","0","2","3","34.39","M","G12D","0","0","0","0","Con Patient 77","5-FU + RT","34.39","mucosa"
"GSM2325518","Patient 78 mucosa control sample","GSM2325518","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 78","age: 63.7","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 88.83","death due to tumor: 0","survival time (month): 88.83","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325518/suppl/GSM2325518_US22502691_252665211168_S01_GE1_107_Sep09_1_2.txt.gz","34127","63.7","0","0","3","3","88.83","F","G12D","0","1","0","0","Con Patient 78","5-FU + RT","88.83","mucosa"
"GSM2325519","Patient 79 mucosa control sample","GSM2325519","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 79","age: 66.8","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 79.63","death due to tumor: 0","survival time (month): 79.63","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325519/suppl/GSM2325519_US22502691_252665211225_S01_GE1_107_Sep09_1_2.txt.gz","34127","66.8","0","0","0","3","79.63","F","WT","0","0","0","0","Con Patient 79","5-FU + RT","79.63","mucosa"
"GSM2325520","Patient 80 mucosa control sample","GSM2325520","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 80","age: 71.5","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 73.48","death due to tumor: 0","survival time (month): 82.82","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325520/suppl/GSM2325520_US22502691_252665211166_S01_GE1_107_Sep09_1_4.txt.gz","34127","71.5","1","0","3","4","73.48","F","WT","1","1","0","0","Con Patient 80","5-FU + RT","82.82","mucosa"
"GSM2325521","Patient 81 mucosa control sample","GSM2325521","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 81","age: 76.8","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 77.85","death due to tumor: 0","survival time (month): 77.85","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325521/suppl/GSM2325521_US22502691_252665211212_S01_GE1_107_Sep09_1_4.txt.gz","34127","76.8","0","0","3","3","77.85","M","WT","0","1","0","0","Con Patient 81","5-FU + RT","77.85","mucosa"
"GSM2325522","Patient 82 mucosa control sample","GSM2325522","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 82","age: 76.5","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 75.48","death due to tumor: 0","survival time (month): 75.48","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325522/suppl/GSM2325522_US22502691_252665211163_S01_GE1_107_Sep09_1_2.txt.gz","34127","76.5","0","0","0","3","75.48","F","WT","0","0","0","0","Con Patient 82","5-FU + RT","75.48","mucosa"
"GSM2325523","Patient 83 mucosa control sample","GSM2325523","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 83","age: 58.3","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 96.03","death due to tumor: 0","survival time (month): 96.03","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325523/suppl/GSM2325523_US22502691_252665211138_S01_GE1_107_Sep09_1_2.txt.gz","34127","58.3","0","0","3","3","96.03","F","WT","2","1","0","0","Con Patient 83","5-FU + RT","96.03","mucosa"
"GSM2325524","Patient 84 mucosa control sample","GSM2325524","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 84","age: 76.7","gender: M","tissue: mucosa","kras mutation: G12A","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 98.7","death due to tumor: 0","survival time (month): 98.7","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325524/suppl/GSM2325524_US22502691_252665211156_S01_GE1_107_Sep09_1_2.txt.gz","34127","76.7","0","0","3","3","98.7","M","G12A","1","0","0","0","Con Patient 84","5-FU + RT","98.7","mucosa"
"GSM2325525","Patient 85 mucosa control sample","GSM2325525","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 85","age: 62.6","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 34.06","death due to tumor: 1","survival time (month): 79.5","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325525/suppl/GSM2325525_US22502691_252665211210_S01_GE1_107_Sep09_1_4.txt.gz","34127","62.6","1","1","4","3","34.06","F","G12D","0","1","0","0","Con Patient 85","5-FU + RT","79.5","mucosa"
"GSM2325526","Patient 86 mucosa control sample","GSM2325526","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 86","age: 51.2","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 76.87","death due to tumor: 0","survival time (month): 76.87","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325526/suppl/GSM2325526_US22502691_252665211192_S01_GE1_107_Sep09_1_2.txt.gz","34127","51.2","0","0","1","3","76.87","M","WT","0","0","0","0","Con Patient 86","5-FU + RT","76.87","mucosa"
"GSM2325527","Patient 87 mucosa control sample","GSM2325527","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 87","age: 67.8","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 29.82","death due to tumor: 0","survival time (month): 29.82","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325527/suppl/GSM2325527_US22502691_252665211214_S01_GE1_107_Sep09_1_2.txt.gz","34127","67.8","0","0","3","3","29.82","F","WT","1","1","0","0","Con Patient 87","5-FU + RT","29.82","mucosa"
"GSM2325528","Patient 88 mucosa control sample","GSM2325528","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 88","age: 63.4","gender: M","tissue: mucosa","kras mutation: G12A","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 90.02","death due to tumor: 0","survival time (month): 90.02","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325528/suppl/GSM2325528_US22502691_252665211189_S01_GE1_107_Sep09_1_2.txt.gz","34127","63.4","0","0","2","3","90.02","M","G12A","0","1","0","0","Con Patient 88","5-FU + RT","90.02","mucosa"
"GSM2325529","Patient 89 mucosa control sample","GSM2325529","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 89","age: 76.3","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 71.61","death due to tumor: 0","survival time (month): 71.61","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325529/suppl/GSM2325529_US22502691_252665211216_S01_GE1_107_Sep09_1_4.txt.gz","34127","76.3","0","0","1","3","71.61","F","G12D","0","0","0","0","Con Patient 89","5-FU + Oxaliplatin + RT","71.61","mucosa"
"GSM2325530","Patient 90 mucosa control sample","GSM2325530","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 90","age: 41.8","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 94.26","death due to tumor: 0","survival time (month): 94.26","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325530/suppl/GSM2325530_US22502691_252665211152_S01_GE1_107_Sep09_1_2.txt.gz","34127","41.8","0","0","2","3","94.26","F","G12D","1","1","0","0","Con Patient 90","5-FU + Oxaliplatin + RT","94.26","mucosa"
"GSM2325531","Patient 91 mucosa control sample","GSM2325531","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 91","age: 58.1","gender: M","tissue: mucosa","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 91.63","death due to tumor: 0","survival time (month): 91.63","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325531/suppl/GSM2325531_US22502691_252665211090_S01_GE1_107_Sep09_1_2.txt.gz","34127","58.1","0","0","3","3","91.63","M","G12V","0","0","0","0","Con Patient 91","5-FU + Oxaliplatin + RT","91.63","mucosa"
"GSM2325532","Patient 92 mucosa control sample","GSM2325532","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 92","age: 65.8","gender: M","tissue: mucosa","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 60.79","death due to tumor: 0","survival time (month): 60.79","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325532/suppl/GSM2325532_US22502691_252665211184_S01_GE1_107_Sep09_1_2.txt.gz","34127","65.8","0","0","2","3","60.79","M","G13D","0","1","0","0","Con Patient 92","5-FU + Oxaliplatin + RT","60.79","mucosa"
"GSM2325533","Patient 93 mucosa control sample","GSM2325533","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 93","age: 59.5","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 63.52","death due to tumor: 0","survival time (month): 63.52","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325533/suppl/GSM2325533_US22502691_252665211157_S01_GE1_107_Sep09_1_4.txt.gz","34127","59.5","0","0","0","3","63.52","F","G12D","0","1","0","0","Con Patient 93","5-FU + Oxaliplatin + RT","63.52","mucosa"
"GSM2325534","Patient 94 mucosa control sample","GSM2325534","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 94","age: 53.7","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 27.12","death due to tumor: 1","survival time (month): 33.6","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325534/suppl/GSM2325534_US22502691_252665211165_S01_GE1_107_Sep09_1_2.txt.gz","34127","53.7","1","1","3","3","27.12","M","WT","1","1","0","0","Con Patient 94","5-FU + Oxaliplatin + RT","33.6","mucosa"
"GSM2325535","Patient 95 mucosa control sample","GSM2325535","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 95","age: 56.9","gender: M","tissue: mucosa","kras mutation: A146T","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 87.35","death due to tumor: 0","survival time (month): 87.35","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325535/suppl/GSM2325535_US22502691_252665211087_S01_GE1_107_Sep09_1_4.txt.gz","34127","56.9","0","0","0","3","87.35","M","A146T","0","1","0","0","Con Patient 95","5-FU + RT","87.35","mucosa"
"GSM2325536","Patient 96 mucosa control sample","GSM2325536","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 96","age: 60.7","gender: M","tissue: mucosa","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 2","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 109.32","death due to tumor: 0","survival time (month): 109.32","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325536/suppl/GSM2325536_US22502691_252665211077_S01_GE1_107_Sep09_1_4.txt.gz","34127","60.7","0","0","0","2","109.32","M","G13D","0","1","0","0","Con Patient 96","5-FU + RT","109.32","mucosa"
"GSM2325537","Patient 97 mucosa control sample","GSM2325537","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 97","age: 64.1","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 46.62","death due to tumor: 1","survival time (month): 73.48","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325537/suppl/GSM2325537_US22502691_252665211217_S01_GE1_107_Sep09_1_4.txt.gz","34127","64.1","1","1","4","3","46.62","F","WT","0","0","0","0","Con Patient 97","5-FU + RT","73.48","mucosa"
"GSM2325538","Patient 98 mucosa control sample","GSM2325538","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 98","age: 55.5","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -3.78","death due to tumor: 1","survival time (month): 25.51","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325538/suppl/GSM2325538_US22502691_252665211187_S01_GE1_107_Sep09_1_2.txt.gz","34127","55.5","1","1","3","3","-3.78","M","WT","1","1","1","0","Con Patient 98","5-FU + RT","25.51","mucosa"
"GSM2325539","Patient 99 mucosa control sample","GSM2325539","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 99","age: 50","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 12.62","death due to tumor: 0","survival time (month): 105.14","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325539/suppl/GSM2325539_US22502691_252665211159_S01_GE1_107_Sep09_1_4.txt.gz","34127","50","1","0","2","3","12.62","M","WT","0","0","0","0","Con Patient 99","5-FU + RT","105.14","mucosa"
"GSM2325540","Patient 100 mucosa control sample","GSM2325540","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 100","age: 35.7","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 68.65","death due to tumor: 1","survival time (month): 91.53","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325540/suppl/GSM2325540_US22502691_252665211170_S01_GE1_107_Sep09_1_2.txt.gz","34127","35.7","1","1","3","3","68.65","M","WT","1","1","0","0","Con Patient 100","5-FU + RT","91.53","mucosa"
"GSM2325541","Patient 101 mucosa control sample","GSM2325541","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 101","age: 77.8","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 91.13","death due to tumor: 0","survival time (month): 91.13","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325541/suppl/GSM2325541_US22502691_252665211161_S01_GE1_107_Sep09_1_4.txt.gz","34127","77.8","0","0","3","3","91.13","M","WT","1","0","0","0","Con Patient 101","5-FU + RT","91.13","mucosa"
"GSM2325542","Patient 102 mucosa control sample","GSM2325542","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 102","age: 65.1","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 79.79","death due to tumor: 0","survival time (month): 79.79","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325542/suppl/GSM2325542_US22502691_252665211188_S01_GE1_107_Sep09_1_4.txt.gz","34127","65.1","0","0","2","3","79.79","M","WT","0","1","0","0","Con Patient 102","5-FU + RT","79.79","mucosa"
"GSM2325543","Patient 103 mucosa control sample","GSM2325543","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 103","age: 74.6","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 18.64","death due to tumor: 1","survival time (month): 24.39","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325543/suppl/GSM2325543_US22502691_252665211220_S01_GE1_107_Sep09_1_4.txt.gz","34127","74.6","1","1","3","3","18.64","F","G12D","0","1","0","0","Con Patient 103","5-FU + Oxaliplatin + RT","24.39","mucosa"
"GSM2325544","Patient 104 mucosa control sample","GSM2325544","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 104","age: 63","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 100.7","death due to tumor: 0","survival time (month): 100.7","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325544/suppl/GSM2325544_US22502691_252665211185_S01_GE1_107_Sep09_1_4.txt.gz","34127","63","0","0","2","3","100.7","M","WT","0","1","0","0","Con Patient 104","5-FU + Oxaliplatin + RT","100.7","mucosa"
"GSM2325545","Patient 105 mucosa control sample","GSM2325545","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 105","age: 73.3","gender: M","tissue: mucosa","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 85.84","death due to tumor: 0","survival time (month): 85.84","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325545/suppl/GSM2325545_US22502691_252665211163_S01_GE1_107_Sep09_1_4.txt.gz","34127","73.3","0","0","3","3","85.84","M","G13D","0","1","0","0","Con Patient 105","5-FU + Oxaliplatin + RT","85.84","mucosa"
"GSM2325546","Patient 106 mucosa control sample","GSM2325546","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 106","age: 73.3","gender: M","tissue: mucosa","kras mutation: G12A","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 75.72","death due to tumor: 0","survival time (month): 75.72","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325546/suppl/GSM2325546_US22502691_252665211089_S01_GE1_107_Sep09_1_4.txt.gz","34127","73.3","0","0","3","3","75.72","M","G12A","0","1","0","0","Con Patient 106","5-FU + RT","75.72","mucosa"
"GSM2325547","Patient 107 mucosa control sample","GSM2325547","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 107","age: 54.8","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 33.11","death due to tumor: 0","survival time (month): 78.84","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325547/suppl/GSM2325547_US22502691_252665211105_S01_GE1_107_Sep09_1_4.txt.gz","34127","54.8","1","0","1","3","33.11","M","WT","2","1","0","0","Con Patient 107","5-FU + RT","78.84","mucosa"
"GSM2325548","Patient 108 mucosa control sample","GSM2325548","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 108","age: 61.5","gender: M","tissue: mucosa","kras mutation: A146T","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 2.4","death due to tumor: 0","survival time (month): 2.4","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325548/suppl/GSM2325548_US22502691_252665211156_S01_GE1_107_Sep09_1_4.txt.gz","34127","61.5","0","0","3","3","2.4","M","A146T","1","1","0","0","Con Patient 108","5-FU + Oxaliplatin + RT","2.4","mucosa"
"GSM2325549","Patient 109 mucosa control sample","GSM2325549","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 109","age: 63.2","gender: F","tissue: mucosa","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 14.99","death due to tumor: 1","survival time (month): 29.46","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325549/suppl/GSM2325549_US22502691_252665211221_S01_GE1_107_Sep09_1_4.txt.gz","34127","63.2","1","1","3","3","14.99","F","G12V","0","1","0","0","Con Patient 109","5-FU + RT","29.46","mucosa"
"GSM2325550","Patient 110 mucosa control sample","GSM2325550","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 110","age: 63.9","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 23.05","death due to tumor: 0","survival time (month): 23.05","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325550/suppl/GSM2325550_US22502691_252665211067_S01_GE1_107_Sep09_1_2.txt.gz","34127","63.9","0","0","2","3","23.05","M","WT","0","1","0","0","Con Patient 110","5-FU + Oxaliplatin + RT","23.05","mucosa"
"GSM2325551","Patient 111 mucosa control sample","GSM2325551","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 111","age: 75.5","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 12.82","death due to tumor: 1","survival time (month): 20.32","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325551/suppl/GSM2325551_US22502691_252665211226_S01_GE1_107_Sep09_1_4.txt.gz","34127","75.5","1","1","1","3","12.82","M","WT","0","0","0","0","Con Patient 111","5-FU + Oxaliplatin + RT","20.32","mucosa"
"GSM2325552","Patient 112 mucosa control sample","GSM2325552","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 112","age: 68.3","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 2","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 95.74","death due to tumor: 0","survival time (month): 95.74","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325552/suppl/GSM2325552_US22502691_252665211099_S01_GE1_107_Sep09_1_4.txt.gz","34127","68.3","0","0","0","2","95.74","F","WT","0","1","0","0","Con Patient 112","5-FU + Oxaliplatin + RT","95.74","mucosa"
"GSM2325553","Patient 113 mucosa control sample","GSM2325553","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 113","age: 51.1","gender: F","tissue: mucosa","kras mutation: Q61L","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 18.18","death due to tumor: 0","survival time (month): 36.33","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325553/suppl/GSM2325553_US22502691_252665211178_S01_GE1_107_Sep09_1_2.txt.gz","34127","51.1","1","0","4","3","18.18","F","Q61L","0","1","0","0","Con Patient 113","5-FU + Oxaliplatin + RT","36.33","mucosa"
"GSM2325554","Patient 114 mucosa control sample","GSM2325554","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 114","age: 46.3","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 96.13","death due to tumor: 0","survival time (month): 96.13","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325554/suppl/GSM2325554_US22502691_252665211180_S01_GE1_107_Sep09_1_4.txt.gz","34127","46.3","0","0","0","3","96.13","F","WT","0","1","0","0","Con Patient 114","5-FU + Oxaliplatin + RT","96.13","mucosa"
"GSM2325555","Patient 115 mucosa control sample","GSM2325555","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 115","age: 59.4","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 73.38","death due to tumor: 0","survival time (month): 73.38","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325555/suppl/GSM2325555_US22502691_252665211075_S01_GE1_107_Sep09_1_2.txt.gz","34127","59.4","0","0","3","3","73.38","F","WT","1","1","0","0","Con Patient 115","5-FU + Oxaliplatin + RT","73.38","mucosa"
"GSM2325556","Patient 116 mucosa control sample","GSM2325556","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 116","age: 70.9","gender: F","tissue: mucosa","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 33.14","death due to tumor: 0","survival time (month): 45.57","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325556/suppl/GSM2325556_US22502691_252665211083_S01_GE1_107_Sep09_1_2.txt.gz","34127","70.9","1","0","3","3","33.14","F","G12V","0","1","0","0","Con Patient 116","5-FU + RT","45.57","mucosa"
"GSM2325557","Patient 117 mucosa control sample","GSM2325557","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 117","age: 59.8","gender: M","tissue: mucosa","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 64.87","death due to tumor: 0","survival time (month): 64.87","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325557/suppl/GSM2325557_US22502691_252665211167_S01_GE1_107_Sep09_1_4.txt.gz","34127","59.8","0","0","3","3","64.87","M","G12V","0","1","0","0","Con Patient 117","5-FU + RT","64.87","mucosa"
"GSM2325558","Patient 118 mucosa control sample","GSM2325558","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 118","age: 81.1","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 44.61","death due to tumor: 0","survival time (month): 44.61","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325558/suppl/GSM2325558_US22502691_252665211174_S01_GE1_107_Sep09_1_4.txt.gz","34127","81.1","0","0","3","3","44.61","M","WT","2","1","0","0","Con Patient 118","5-FU + RT","44.61","mucosa"
"GSM2325559","Patient 119 mucosa control sample","GSM2325559","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 119","age: 73","gender: F","tissue: mucosa","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 70.19","death due to tumor: 0","survival time (month): 70.19","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325559/suppl/GSM2325559_US22502691_252665211215_S01_GE1_107_Sep09_1_4.txt.gz","34127","73","0","0","3","3","70.19","F","G13D","0","1","0","0","Con Patient 119","5-FU + RT","70.19","mucosa"
"GSM2325560","Patient 120 mucosa control sample","GSM2325560","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 120","age: 70.9","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 71.74","death due to tumor: 0","survival time (month): 71.74","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325560/suppl/GSM2325560_US22502691_252665211211_S01_GE1_107_Sep09_1_4.txt.gz","34127","70.9","0","0","3","3","71.74","M","WT","0","0","0","0","Con Patient 120","5-FU + Oxaliplatin + RT","71.74","mucosa"
"GSM2325561","Patient 121 mucosa control sample","GSM2325561","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 121","age: 63.8","gender: M","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 24.99","death due to tumor: 1","survival time (month): 49.91","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325561/suppl/GSM2325561_US22502691_252665211176_S01_GE1_107_Sep09_1_4.txt.gz","34127","63.8","1","1","4","4","24.99","M","G12D","1","1","0","0","Con Patient 121","5-FU + Oxaliplatin + RT","49.91","mucosa"
"GSM2325562","Patient 122 mucosa control sample","GSM2325562","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 122","age: 63.7","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 63.42","death due to tumor: 0","survival time (month): 63.42","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325562/suppl/GSM2325562_US22502691_252665211190_S01_GE1_107_Sep09_1_2.txt.gz","34127","63.7","0","0","3","3","63.42","M","WT","0","0","0","0","Con Patient 122","5-FU + RT","63.42","mucosa"
"GSM2325563","Patient 123 mucosa control sample","GSM2325563","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 123","age: 72.3","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 0","death due to tumor: 0","survival time (month): 91.43","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325563/suppl/GSM2325563_US22502691_252665211210_S01_GE1_107_Sep09_1_2.txt.gz","34127","72.3","1","0","2","3","0","M","WT","0","1","1","1","Con Patient 123","5-FU + RT","91.43","mucosa"
"GSM2325564","Patient 124 mucosa control sample","GSM2325564","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 124","age: 51.9","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): -3.19","death due to tumor: 1","survival time (month): 8.81","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325564/suppl/GSM2325564_US22502691_252665211090_S01_GE1_107_Sep09_1_4.txt.gz","34127","51.9","1","1","3","3","-3.19","M","WT","0","1","1","1","Con Patient 124","5-FU + Oxaliplatin + RT","8.81","mucosa"
"GSM2325565","Patient 125 mucosa control sample","GSM2325565","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 125","age: 69.6","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 63.72","death due to tumor: 0","survival time (month): 63.72","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325565/suppl/GSM2325565_US22502691_252665211202_S01_GE1_107_Sep09_1_2.txt.gz","34127","69.6","0","0","0","3","63.72","F","WT","0","1","0","0","Con Patient 125","5-FU + RT","63.72","mucosa"
"GSM2325566","Patient 126 mucosa control sample","GSM2325566","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 126","age: 65.1","gender: F","tissue: mucosa","kras mutation: G12C","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 4","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 60.53","death due to tumor: 0","survival time (month): 60.53","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325566/suppl/GSM2325566_US22502691_252665211202_S01_GE1_107_Sep09_1_4.txt.gz","34127","65.1","0","0","4","3","60.53","F","G12C","0","1","0","0","Con Patient 126","5-FU + Oxaliplatin + RT","60.53","mucosa"
"GSM2325567","Patient 127 mucosa control sample","GSM2325567","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 127","age: 60.2","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + Cetuximab + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 73.84","death due to tumor: 0","survival time (month): 73.84","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325567/suppl/GSM2325567_US22502691_252665211211_S01_GE1_107_Sep09_1_2.txt.gz","34127","60.2","0","0","0","3","73.84","M","WT","0","1","0","0","Con Patient 127","5-FU + Oxaliplatin + Cetuximab + RT","73.84","mucosa"
"GSM2325568","Patient 128 mucosa control sample","GSM2325568","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 128","age: 56.3","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 65.72","death due to tumor: 0","survival time (month): 65.72","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325568/suppl/GSM2325568_US22502691_252665211177_S01_GE1_107_Sep09_1_4.txt.gz","34127","56.3","0","0","3","3","65.72","F","G12D","1","1","0","0","Con Patient 128","5-FU + RT","65.72","mucosa"
"GSM2325569","Patient 129 mucosa control sample","GSM2325569","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 129","age: 66.2","gender: M","tissue: mucosa","kras mutation: NA","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 60.46","death due to tumor: 0","survival time (month): 60.46","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325569/suppl/GSM2325569_US22502691_252665211209_S01_GE1_107_Sep09_1_4.txt.gz","34127","66.2","0","0","3","3","60.46","M","NA","0","1","0","0","Con Patient 129","5-FU + Oxaliplatin + RT","60.46","mucosa"
"GSM2325570","Patient 130 mucosa control sample","GSM2325570","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 130","age: 79.9","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 72.43","death due to tumor: 0","survival time (month): 72.43","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325570/suppl/GSM2325570_US22502691_252665211074_S01_GE1_107_Sep09_1_4.txt.gz","34127","79.9","0","0","3","3","72.43","M","WT","0","1","0","0","Con Patient 130","5-FU + Oxaliplatin + RT","72.43","mucosa"
"GSM2325571","Patient 131 mucosa control sample","GSM2325571","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 131","age: 67.5","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 68.48","death due to tumor: 0","survival time (month): 68.48","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325571/suppl/GSM2325571_US22502691_252665211168_S01_GE1_107_Sep09_1_4.txt.gz","34127","67.5","0","0","3","3","68.48","M","WT","0","1","0","0","Con Patient 131","5-FU + Oxaliplatin + RT","68.48","mucosa"
"GSM2325572","Patient 132 mucosa control sample","GSM2325572","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 132","age: 60.6","gender: M","tissue: mucosa","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + Cetuximab + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 63.09","death due to tumor: 0","survival time (month): 63.09","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325572/suppl/GSM2325572_US22502691_252665211098_S01_GE1_107_Sep09_1_4.txt.gz","34127","60.6","0","0","2","3","63.09","M","G12V","0","0","0","0","Con Patient 132","5-FU + Oxaliplatin + Cetuximab + RT","63.09","mucosa"
"GSM2325573","Patient 133 mucosa control sample","GSM2325573","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 133","age: 51.8","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + Cetuximab + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 71.24","death due to tumor: 0","survival time (month): 71.24","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325573/suppl/GSM2325573_US22502691_252665211205_S01_GE1_107_Sep09_1_4.txt.gz","34127","51.8","0","0","2","3","71.24","F","WT","0","1","0","0","Con Patient 133","5-FU + Oxaliplatin + Cetuximab + RT","71.24","mucosa"
"GSM2325574","Patient 134 mucosa control sample","GSM2325574","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 134","age: 57.5","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + Cetuximab + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: NA","lymph node metastasis after rct: 2","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 0","death due to tumor: 1","survival time (month): 3.32","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325574/suppl/GSM2325574_US22502691_252665211194_S01_GE1_107_Sep09_1_2.txt.gz","34127","57.5","1","1","NA","3","0","M","WT","2","1","1","0","Con Patient 134","5-FU + Oxaliplatin + Cetuximab + RT","3.32","mucosa"
"GSM2325575","Patient 135 mucosa control sample","GSM2325575","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 135","age: 54.8","gender: M","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 72.43","death due to tumor: 0","survival time (month): 72.43","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325575/suppl/GSM2325575_US22502691_252665211086_S01_GE1_107_Sep09_1_4.txt.gz","34127","54.8","0","0","1","3","72.43","M","G12D","0","0","0","0","Con Patient 135","5-FU + Oxaliplatin + RT","72.43","mucosa"
"GSM2325576","Patient 136 mucosa control sample","GSM2325576","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 136","age: 73.7","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 24.13","death due to tumor: 0","survival time (month): 61.41","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325576/suppl/GSM2325576_US22502691_252665211162_S01_GE1_107_Sep09_1_2.txt.gz","34127","73.7","1","0","3","3","24.13","F","G12D","0","1","0","0","Con Patient 136","5-FU + RT","61.41","mucosa"
"GSM2325577","Patient 137 mucosa control sample","GSM2325577","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 137","age: 73.9","gender: F","tissue: mucosa","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 23.01","death due to tumor: 1","survival time (month): 42.97","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325577/suppl/GSM2325577_US22502691_252665211181_S01_GE1_107_Sep09_1_2.txt.gz","34127","73.9","1","1","3","3","23.01","F","G13D","1","1","0","0","Con Patient 137","5-FU + RT","42.97","mucosa"
"GSM2325578","Patient 138 mucosa control sample","GSM2325578","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 138","age: 50.5","gender: F","tissue: mucosa","kras mutation: A146T","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 42.54","death due to tumor: 0","survival time (month): 42.54","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325578/suppl/GSM2325578_US22502691_252665211194_S01_GE1_107_Sep09_1_4.txt.gz","34127","50.5","0","0","3","3","42.54","F","A146T","0","1","0","0","Con Patient 138","5-FU + RT","42.54","mucosa"
"GSM2325579","Patient 139 mucosa control sample","GSM2325579","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 139","age: 77","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 82.88","death due to tumor: 0","survival time (month): 82.88","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325579/suppl/GSM2325579_US22502691_252665211083_S01_GE1_107_Sep09_1_4.txt.gz","34127","77","0","0","3","3","82.88","F","WT","1","1","0","0","Con Patient 139","5-FU + Oxaliplatin + RT","82.88","mucosa"
"GSM2325580","Patient 140 mucosa control sample","GSM2325580","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 140","age: 41.8","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 71.8","death due to tumor: 0","survival time (month): 71.8","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325580/suppl/GSM2325580_US22502691_252665211187_S01_GE1_107_Sep09_1_4.txt.gz","34127","41.8","0","0","2","3","71.8","F","G12D","0","1","0","0","Con Patient 140","5-FU + Oxaliplatin + RT","71.8","mucosa"
"GSM2325581","Patient 141 mucosa control sample","GSM2325581","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 141","age: 73.1","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 63.48","death due to tumor: 0","survival time (month): 63.48","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325581/suppl/GSM2325581_US22502691_252665211182_S01_GE1_107_Sep09_1_4.txt.gz","34127","73.1","0","0","0","3","63.48","M","WT","0","1","0","0","Con Patient 141","5-FU + RT","63.48","mucosa"
"GSM2325582","Patient 142 mucosa control sample","GSM2325582","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 142","age: 67","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 78.71","death due to tumor: 0","survival time (month): 78.71","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325582/suppl/GSM2325582_US22502691_252665211141_S01_GE1_107_Sep09_1_4.txt.gz","34127","67","0","0","0","4","78.71","M","WT","0","1","0","0","Con Patient 142","5-FU + RT","78.71","mucosa"
"GSM2325583","Patient 143 mucosa control sample","GSM2325583","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 143","age: 61.9","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 73.38","death due to tumor: 0","survival time (month): 73.38","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325583/suppl/GSM2325583_US22502691_252665211259_S01_GE1_107_Sep09_1_2.txt.gz","34127","61.9","0","0","0","3","73.38","M","WT","0","1","0","0","Con Patient 143","5-FU + Oxaliplatin + RT","73.38","mucosa"
"GSM2325584","Patient 144 mucosa control sample","GSM2325584","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 144","age: 42","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 77.59","death due to tumor: 0","survival time (month): 77.59","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325584/suppl/GSM2325584_US22502691_252665211169_S01_GE1_107_Sep09_1_4.txt.gz","34127","42","0","0","0","3","77.59","M","WT","0","0","0","0","Con Patient 144","5-FU + Oxaliplatin + RT","77.59","mucosa"
"GSM2325585","Patient 145 mucosa control sample","GSM2325585","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 145","age: 68.7","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 40.67","death due to tumor: 0","survival time (month): 40.67","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325585/suppl/GSM2325585_US22502691_252665211228_S01_GE1_107_Sep09_1_4.txt.gz","34127","68.7","0","0","2","3","40.67","M","WT","0","1","0","0","Con Patient 145","5-FU + Oxaliplatin + RT","40.67","mucosa"
"GSM2325586","Patient 146 mucosa control sample","GSM2325586","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 146","age: 59.4","gender: F","tissue: mucosa","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 1","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 1","cancer recurrance after surgery: 1","disease free time (month): 0","death due to tumor: 1","survival time (month): 35.8","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325586/suppl/GSM2325586_US22502691_252665211071_S01_GE1_107_Sep09_1_2.txt.gz","34127","59.4","1","1","3","3","0","F","G12V","2","1","1","1","Con Patient 146","5-FU + Oxaliplatin + RT","35.8","mucosa"
"GSM2325587","Patient 147 mucosa control sample","GSM2325587","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 147","age: 78.8","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 64.5","death due to tumor: 0","survival time (month): 64.5","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325587/suppl/GSM2325587_US22502691_252665211173_S01_GE1_107_Sep09_1_2.txt.gz","34127","78.8","0","0","3","3","64.5","F","WT","0","1","0","0","Con Patient 147","5-FU + Oxaliplatin + RT","64.5","mucosa"
"GSM2325588","Patient 148 mucosa control sample","GSM2325588","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 148","age: 57.3","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 72.56","death due to tumor: 0","survival time (month): 72.56","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325588/suppl/GSM2325588_US22502691_252665211221_S01_GE1_107_Sep09_1_2.txt.gz","34127","57.3","0","0","0","3","72.56","M","WT","0","1","0","0","Con Patient 148","5-FU + Oxaliplatin + RT","72.56","mucosa"
"GSM2325589","Patient 149 mucosa control sample","GSM2325589","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 149","age: 63.7","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 74.33","death due to tumor: 0","survival time (month): 74.33","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325589/suppl/GSM2325589_US22502691_252665211218_S01_GE1_107_Sep09_1_4.txt.gz","34127","63.7","0","0","3","3","74.33","F","WT","0","1","0","0","Con Patient 149","5-FU + Oxaliplatin + RT","74.33","mucosa"
"GSM2325590","Patient 150 mucosa control sample","GSM2325590","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 150","age: 60.7","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 27.32","death due to tumor: 1","survival time (month): 40.83","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325590/suppl/GSM2325590_US22502691_252665211101_S01_GE1_107_Sep09_1_2.txt.gz","34127","60.7","1","1","3","3","27.32","M","WT","0","1","0","0","Con Patient 150","5-FU + Oxaliplatin + RT","40.83","mucosa"
"GSM2325591","Patient 151 mucosa control sample","GSM2325591","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 151","age: 62.5","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 72.1","death due to tumor: 0","survival time (month): 72.1","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325591/suppl/GSM2325591_US22502691_252665211219_S01_GE1_107_Sep09_1_2.txt.gz","34127","62.5","0","0","2","3","72.1","M","WT","0","1","0","0","Con Patient 151","5-FU + RT","72.1","mucosa"
"GSM2325592","Patient 152 mucosa control sample","GSM2325592","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 152","age: 51.7","gender: F","tissue: mucosa","kras mutation: G12V","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 69.04","death due to tumor: 0","survival time (month): 69.04","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325592/suppl/GSM2325592_US22502691_252665211152_S01_GE1_107_Sep09_1_4.txt.gz","34127","51.7","0","0","3","3","69.04","F","G12V","1","1","0","0","Con Patient 152","5-FU + Oxaliplatin + RT","69.04","mucosa"
"GSM2325593","Patient 153 mucosa control sample","GSM2325593","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 153","age: 56.5","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 70.09","death due to tumor: 0","survival time (month): 70.09","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325593/suppl/GSM2325593_US22502691_252665211164_S01_GE1_107_Sep09_1_2.txt.gz","34127","56.5","0","0","3","3","70.09","F","WT","0","1","0","0","Con Patient 153","5-FU + Oxaliplatin + RT","70.09","mucosa"
"GSM2325594","Patient 154 mucosa control sample","GSM2325594","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 154","age: 74.9","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 2.2","death due to tumor: 0","survival time (month): 2.2","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325594/suppl/GSM2325594_US22502691_252665211216_S01_GE1_107_Sep09_1_2.txt.gz","34127","74.9","0","0","2","3","2.2","M","WT","0","1","0","0","Con Patient 154","5-FU + RT","2.2","mucosa"
"GSM2325595","Patient 155 mucosa control sample","GSM2325595","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 155","age: 61.5","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 2","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 2","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 71.54","death due to tumor: 0","survival time (month): 71.54","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325595/suppl/GSM2325595_US22502691_252665211158_S01_GE1_107_Sep09_1_4.txt.gz","34127","61.5","0","0","2","2","71.54","M","WT","0","1","0","0","Con Patient 155","5-FU + RT","71.54","mucosa"
"GSM2325596","Patient 156 mucosa control sample","GSM2325596","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 156","age: 69.9","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 1","lymph node metastasis after rct: 1","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 67.76","death due to tumor: 0","survival time (month): 67.76","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325596/suppl/GSM2325596_US22502691_252665211079_S01_GE1_107_Sep09_1_4.txt.gz","34127","69.9","0","0","1","3","67.76","M","WT","1","0","0","0","Con Patient 156","5-FU + Oxaliplatin + RT","67.76","mucosa"
"GSM2325597","Patient 157 mucosa control sample","GSM2325597","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 157","age: 63.6","gender: F","tissue: mucosa","kras mutation: G13D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 72.03","death due to tumor: 0","survival time (month): 72.03","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325597/suppl/GSM2325597_US22502691_252665211166_S01_GE1_107_Sep09_1_2.txt.gz","34127","63.6","0","0","3","3","72.03","F","G13D","0","1","0","0","Con Patient 157","5-FU + Oxaliplatin + RT","72.03","mucosa"
"GSM2325598","Patient 158 mucosa control sample","GSM2325598","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 158","age: 59","gender: F","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 1","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 1","disease free time (month): 8.45","death due to tumor: 1","survival time (month): 27.12","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325598/suppl/GSM2325598_US22502691_252665211071_S01_GE1_107_Sep09_1_4.txt.gz","34127","59","1","1","3","3","8.45","F","WT","0","1","0","0","Con Patient 158","5-FU + RT","27.12","mucosa"
"GSM2325599","Patient 159 mucosa control sample","GSM2325599","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 159","age: 53.1","gender: F","tissue: mucosa","kras mutation: G12D","preoperative radiochemotherapy (rct): 5-FU + Oxaliplatin + RT","depth of invasion before rct: 3","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 0","lymph node metastasis after rct: 0","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 59.8","death due to tumor: 0","survival time (month): 59.8","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325599/suppl/GSM2325599_US22502691_252665211097_S01_GE1_107_Sep09_1_2.txt.gz","34127","53.1","0","0","0","3","59.8","F","G12D","0","0","0","0","Con Patient 159","5-FU + Oxaliplatin + RT","59.8","mucosa"
"GSM2325600","Patient 160 mucosa control sample","GSM2325600","Public on Nov 28 2017","Sep 22 2016","Nov 29 2017","RNA","1","mucosa","Homo sapiens","patient: Con Patient 160","age: 65.3","gender: M","tissue: mucosa","kras mutation: WT","preoperative radiochemotherapy (rct): 5-FU + RT","depth of invasion before rct: 4","lymph node metastasis before rct: 0","metastasis before rct: 0","depth of invasion after rct: 3","lymph node metastasis after rct: 2","metastasis after rct: 0","cancer recurrance after surgery: 0","disease free time (month): 37.02","death due to tumor: 0","survival time (month): 37.02","During index rectoscopy several biopsies of tumor and normal mucosa were taken and either directly buffered in 4% formalin, stored overnight and embedded in paraffin the next day or immediately transferred into RNAlater (Qiagen, Hilden, Germany). Tissue in RNAlater was stored over night at 4 °C to allow saturation of the entire biopsy and stored at −20 °C until RNA isolation.","total RNA","Using the Qiagen AllPrep® DNA/RNA FFPE kit (Qiagen, Hilden, Germany) according to manufactures recommendation, RNA was isolated from FFPE samples. Using TRIZOL (cat. no. 15596-018, Life Technologies, Rockeville, MD, USA) RNA was extracted from RNAlater biopsies. All samples underwent strict quality assessment, nucleic acid quantity, and purity was determined using the NanoDrop spectrophotometer ND1000 (Thermo Fisher Scientific Inc., Waltham, MA, USA), quality and integrity was assessed by a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).","Cy3","600ng of total RNA was amplified and transcribed into fluorescence labeled cRNA following the Low RNA Input linear Amplification Kit Plus, One Color protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339).","9606","cRNA was hybridized to the Human 4 × 44 K array platform from Agilent Technologies (G4112F) as recommended by the manufacturer.","Cy3 intensities were detected by one-color scanning using an Agilent DNA microarray scanner (G2505B) at 5 micron resolution. Scanned image files were visually inspected for artifacts and then analyzed using the Agilent feature extraction software (Agilent Technologies, Santa Clara, CA, USA).","Raw data were log2 transformed and normalized to 75 percentile according to Agilent protocol.","GPL13497","Yue,,Hu","yue.hu@nih.gov","Thomas Ried","Genetic","NCI","50 South Drive, Bldg. 50, Rm. 1408","Bethesda","MD","20892","USA","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2325nnn/GSM2325600/suppl/GSM2325600_US22502691_252665211078_S01_GE1_107_Sep09_1_2.txt.gz","34127","65.3","0","0","3","4","37.02","M","WT","2","0","0","0","Con Patient 160","5-FU + RT","37.02","mucosa"
